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Zusammenfassung 
Ursprüngliche Methoden der Entdeckung neuer Naturstoffe aus Bakterien, waren zunächst davon 
abhängig, diese im Labor zu kultivieren, wodurch das Auffinden neuer chemischer Strukturen sehr 
arbeits- und zeitintensiv war. Oftmals kam es dabei zur Wiederentdeckung schon bekannter 
Naturstoffe. Die heutzutage stetig steigende Verfügbarkeit an Genomsequenzen, kommt für 
Wissenschaftler einem wahren Schatzfund gleich. Mittels bioinformatischen Genanalyseprogrammen 
wie antiSMASH, können Biosynthesewege aus genetischen Sequenzen identifiziert werden.1 Leider 
ist es mit solchen automatisierten Programmen schwierig herauszufinden, wie sich geringfügige 
genetische Unterschiede in Biosynthesegenclustern, auf die daraus resultierenden chemischen 
Strukturen auswirken. Dies erschwert die Priorisierung von Stämmen und kann oftmals zu falschen 
Vorhersagen chemischer Strukturen führen. 
Im Rahmen dieser Doktorarbeit wurde das metabolische Potential von Nocardia, einem wenig 
untersuchten, aber vielversprechendem actinobakteriellen Genus, mittels genomgestützter 
Vorgehensweise, untersucht.2 Durch BiG-SCAPE (Biosynthetic Genes Similarity Clustering and 
Prospecting Engine) konnten Sequenzähnlichkeitsnetzwerke generiert werden, die eine deutliche 
Unterteilung in Genclusterfamilien zeigten und eine Fülle an biosynthetischen Genclustern 
zahlreicher Klassen offenbarten (z.B. Polyketid-, nicht-ribosomale Peptid- und 
Terpenoidstoffwechselwege).3 Exemplarisch wurde untersucht, wie sich geringfügige genetische 
Unterschiede in hoch konservierten nocobactinähnlichen Biosynthesestoffwechselwegen, auf die 
chemisch strukturelle Diversität auswirken.4 
Die Analyse ausgewählter Nocardiastämme mittels LC-MS (Flüssigchromatographie mit 
Massenspektrometrie-Kopplung) und GNPS (Global Natural Product Social Molecular Networking) 
konnte zeigen, dass sich geringfügige Unterschiede in nocobactinähnlichen Genclustern, bestimmten 
nocobactinähnlichen Siderophoren zuordnen lassen.5, 6 Die neuartigen Siderophore Terpenibactin A-
C wurden mittels LC-MS, NMR-Spektroskopie (Kernspinresonanzspektroskopie) und Bioassays 
charakterisiert.7 Des Weiteren wurden neuartige lösliche Nocobactine mittels LC-MS identifiziert. 
Interessanterweise produzierten manche Nocardiastämme mycobactinähnliche Siderophore. Durch 
NMR-Spektroskopie konnte die zugehörige chemische Struktur aufgeklärt werden, welche eine hohe 
Ähnlichkeit zu bekannten Virulenzfaktoren aus Mycobakterien aufwies.4, 8 
Das folgende genomgestützte Verfahren verdeutlicht das hohe Potential des Genus Nocardia und 
weist auf die konstitutive Rolle der Nocobactine hin. Diese Doktorarbeit setzt den Grundstein für 
zukünftige Nocardia Genanalysen, zukünftige Untersuchungen anderer seltener Actinobakterien, 
verhindert Wiederentdeckung von Naturstoffen und macht Priorisierung von Stämmen möglich. 
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Summary 
Traditional methods for natural product discovery relied exclusively on cultivation of bacteria in the 
laboratory. Discovery of novel chemistry was laborious and time consuming and frequently resulted 
in the rediscovery of known natural products. The increasing availability of genomic sequences 
represents a huge treasure trove for researchers. Biosynthetic pathways can be readily identified 
from sequence data using genome mining tools such as antiSMASH.1 However, using automated 
bioinformatic genome analysis tools, it is often unclear to what degree genetic variability in 
homologous biosynthetic pathways relates to chemical structural diversity. This makes prioritization 
of microbial strains and compound identification extremely difficult and often leads to incorrect 
prediction of natural product structural diversity. 
In the scope of this thesis, the metabolic potential of Nocardia, an under-investigated but highly 
prolific actinobacterial genus, was assessed using a genomics-guided approach.2 Sequence similarity 
networks generated by BiG-SCAPE (Biosynthetic Genes Similarity Clustering and Prospecting Engine) 
showed the presence of distinct gene cluster families including a plethora of biosynthetic gene 
clusters of various classes including: polyketide; non-ribosomal peptide; and terpenoid pathways.3 
Highly conserved biosynthetic pathways encoding for nocobactin-type siderophores were used to 
exemplify how specific differences in highly related gene clusters correlate to structural diversity in 
the produced compounds.4 
Metabolic profiling of selected Nocardia strains using LC-MS (liquid chromatography-mass 
spectrometry) metabolomics data and GNPS (Global Natural Product Social Molecular Networking) 
revealed related nocobactin-type biosynthetic gene clusters that can indeed be assigned to distinct 
structural types of nocobactin-type siderophores.5, 6 The new nocobactin-type siderophores 
terpenibactins A-C were characterized using LC-MS, NMR (nuclear magnetic resonance) spectroscopy 
and bioassays.7 Furthermore, novel soluble forms of nocobactin-type siderophores were identified 
using LC-MS. Interestingly, some Nocardia strains produced mycobactin-type siderophores, where 
NMR spectroscopy revealed a chemical structure highly similar to known virulence factors from 
mycobacteria.4, 8 
The subsequent comparative genomics and metabolomics approach highlights the potential of the 
highly promising genus Nocardia and points out the constitutive role of nocobactins. It can set the 
foundation for future Nocardia genome mining approaches and thorough assessment of other rare 
actinobacteria, circumventing rediscovery of natural products and facilitating strain prioritization. 
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1. Introduction 
1.1. Background Information 
1.1.1. Natural product discovery 
Natural products are small organic compounds produced by living organisms. The ecological roles can 
be as diverse as their chemical structures and include defense, communication and nutrient 
acquisition.9 Natural products can be derived from primary, but are mainly derived from secondary 
metabolism. Secondary metabolites are considered non-essential for growth or reproduction of 
bacteria and were thought to give the producer a survival advantage over others.10 
Natural products are highly valuable and many of today’s most important compounds for medical 
applications or the pharmaceutical industry.11-13 These unparalleled successful sources for drug 
discovery find use as antibiotics, immunosuppressants or anticancer compounds.11, 14 New antibiotics 
are urgently needed, as bacteria gain resistance to routinely used antibiotics quickly.15 The unique 
chemical stereostructures of some natural products make them extremely hard or impossible to 
synthesize.16 Therefore, scientists often rely on microorganisms that naturally produce natural 
products and often use them as precursors for commercial drug products.17 
1.1.2. The phylum Actinobacteria 
One of the most promising sources for natural products is the bacterial phylum of Actinobacteria.18 It 
includes the deadliest bacterial pathogen Mycobacterium tuberculosis, which is the third leading 
cause of death worldwide after deaths by the HI-Virus and the human pathogen Corynebacterium 
diphtheriae.19 However, the phylum also contains Corynebacterium glutamicum, the industrial 
producer of glutamic acid and contains the genus Streptomyces that has been known as a rich 
resource for discovery of secondary metabolites and is the source of over half of the bioactive 
metabolites from bacteria used in medicine.13, 20, 21 Underexplored bacterial taxa were shown to 
harbor prolific producers of novel bioactive chemistry.22 Nocardia is one underexplored genus from 
the order Actinomycetales with potential for production of bioactive compounds.23 They are closely 
related to Corynebacterium, Rhodococcus and Mycobacterium. Nocardia are aerobic, Gram-positive 
and partially acid-fast actinomycetes, ubiquitously distributed in both aquatic and terrestrial 
habitats.24-26 These saprophytes are able to form branching and filamentous mycelia that can 
fragment into rod-shaped bacteroid non-motile elements.27 
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1.1.3. Pathogenicity of Nocardia 
Originally, Nocardia were foremost known for their facultative and opportunistic pathogenicity. They 
were first described by Edward Nocard in 1888 as causative agents of severe infections of the skin, 
lung or central nervous system in humans and animals causing nocardiosis and have been extensively 
studied by Beaman and others. 28-31 Nocardiosis mainly affects immunocompromised patients and 
leads to high mortality rates. Nevertheless, nocardiosis was also reported from immunocompetent 
patients.2 Despite many Nocardia species being facultative pathogens, some species are clinically 
more frequently associated with nocardiosis patients than others.30, 32-34 These strains are further 
referred to as group 1 pathogens and include N. asteroides, N. abscessus, N. brasiliensis, N. 
cyriacigeorgica, N. farcinica, N. nova, and N. otitidiscaviarum. Further frequently mentioned 
pathogens include N. africana, N. brevicatena, N. kruczakiae, N. paucivorans, N. transvalensis, and N. 
veterana. Group 1 pathogenic Nocardia are analyzed in this study. 
1.1.4. Natural products from Nocardia 
Few studies have focused on secondary metabolites and respective biosynthetic genes in Nocardia 
strains.2 Reports of natural products produced by members of Nocardia are reported scarcely and 
include the β-lactone antibiotics nocardiolactone, nocardicin A and B and the immunosuppressive 
terpenoid antibiotic brasilicardin A amongst few other natural products (Figure 1).35-37 
 
Figure 1: selected known natural products produced by members of the genus Nocardia. Adapted from Männle et al. 
2020.6 
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1.2. Siderophores 
1.2.1. General features and application of siderophores 
Natural products include important chelating molecules, so-called siderophores that are one of the 
few examples of bacterial secondary metabolites where the ecological function is known.38, 39 
Siderophores not only play an important role in microbial iron acquisition, they are also known to be 
virulence factors associated with host colonization in a host-pathogen competition for scarce iron 
(e.g. in Mycobacterium).40, 41 However, interest in the investigation of bacteria extends beyond a 
siderophore’s capacity to bind ferric iron for bacterial survival. In fact, siderophores can find 
application in the field of medicine, as part of antibiotic drug conjugates and iron overload 
therapies.42 They are also used in bioremediation of polluted habitats.43 
1.2.2. Nocobactin NA and nocobactin derivatives from Nocardia 
The lipophilic, membrane-associated siderophore nocobactin NA (Figure 2) has been first described 
in 1974 and was found as a UV-active siderophore from cultures of Nocardia asteroides ATCC 3318 
(later reclassified as Nocardia farcinica IFM 10152) by Ratledge and Snow.44 Structurally, nocobactin 
NA-a and NA-b share a 2-hydroxyphenyl-5-methyl-oxazoline or -oxazole moiety, a N-acetylated or -
formylated N-hydroxylysine that is linked via an ester moiety to a long-chain α-methyl, β-hydroxy 
fatty acid, and a C-terminal N-hydroxy α-amino ε-caprolactam ring (Figure 2). Furthermore, 
cytotoxicity of nocobactin NA has been observed to be higher against cancer cell lines than normal 
cells, which makes the nocobactins also interesting as anticancer compounds.45 Nocobactins were 
reported from other Nocardia spp..46 Differently substituted derivatives of cytotoxic nocobactin NA-a 
and NA-b have been found and include amamistatin A and B, formobactin, brasilibactin A, and 
nocardimicins A-I (Figure 2). 7, 44, 45, 47-51 Nocobactin derivatives show variation in the substitution 
pattern of the 2-OH-phenyl residue, of the oxazole ring system, of the N-hydroxylysine residues and 
in the nature of the fatty acid. It has been reported that nocobactin NA and nocardimicins A-F 
feature an acetyl moiety, whereas nocardimicins G-I, amamistatin A and B, brasilibactin and 
formobactin feature a formyl moiety. Nocobactin-type siderophores exhibit two types of heterocyclic 
ring variants. Nocobactin NA, formobactin, the amamistatins, and nocardimicins A-F show oxazole 
moieties, whereas brasilibactin A and nocardimicins G-I contain oxazoline moieties. Nocobactin-type 
siderophores have already shown outstanding cytotoxic properties (nocobactin NA-a and NA-b, 
brasilibactin A) and have been described as growth inhibitors of tumor cell lines (amamistatins A and 
B).45, 49, 50 Furthermore, the nocardimicins have been found to effectively inhibit muscarinic M3 
receptor binding, a target in the treatment of certain respiratory and gastrointestinal disorders.47, 48 
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Figure 2: selected nocobactin-type and mycobactin-type siderophores by Nocardia spp.. Nocobactin NA-a and Na-b are 
produced by Nocardia farcinica IFM 10152 (formerly known as Nocardia asteroides ATCC 3318).4, 44 Amamistatin A and B 
are produced by Nocardia asteroides SCRC-A2359.49 Formobactin is produced by Nocardia sp. ND20.51 Brasilibactin A is 
produced by Nocardia brasiliensis IFM 0995.50, 52 Nocardimicins A-F are produced by Nocardia sp. TP-A0674 and 
nocardimicins G-I are produced by Nocardia nova JCM 6044.47, 48 BE-32030A-E (mycobactin-type siderophores) are 
produced by Nocardia sp. A32030.53 Mycobactin M15, M16, M17 and M18 are produced by Mycobacterium marinum.8 
Carboxymycobactin is produced by Mycobacterium avium CR1/69.54 
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Despite Mycobacterium mainly producing closely related mycobactins, nocobactins also have been 
reported previously from Mycobacterium marinum (termed as mycobactin M).8 Vice-versa, BE32030 
A-E are the only known mycobactin-type siderophores reported from Nocardia sp. A32030 where no 
associated BGC (biosynthetic gene cluster) was reported (Figure 2).53 Furthermore, soluble forms of 
mycobactins, the so-called carboxymycobactins were reported that feature a carboxylic acid moiety 
attached to the fatty acyl chain.54-56 Several other structurally similar siderophores have been 
reported from Nocardia spp. and other closely related genera including asterobactin, heterobactin A, 
JBIR-16, nocardichelin A, transvalencin Z, and ornibactin-C4 (Figure 3).57-62 
 
Figure 3: siderophores produced by Nocardia spp. and closely related genera. Asterobactin is produced by Nocardia 
asteroides IFM 0959 57. Heterobactin A is produced by Rhodococcus erythropolis PR4.58 Nocardichelins A and B are 
produced by Nocardia acta 3026.60 Ornibactin-C4, -C6, and -C8 are produced by Pseudomonas cepacia.61 Transvalencin Z is 
produced by Nocardia transvalensis IFM 10065.62 
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1.2.3. Nocobactin BGC and nocobactin biosynthesis 
The biosynthetic pathway for nocobactin NA was first reported from Nocardia farcinica IFM 10152 by 
Hoshino et al..4 It was found to consist of ten genes distributed between two genetic loci, whereof 
the first locus consists of eight genes (subcluster I) and the second locus involves two genes 
(subcluster II) located ~180 kb upstream of subcluster I. This split BGC involves a non-linear assembly 
line consisting of three non-ribosomal peptides (NRPSs) and one type I polyketide synthase (PKS) 
module (Figure 4). Subcluster I consists of nbtA, nbtB, nbtC, nbtD, nbtE, nbtF, nbtG and nbtH 
biosynthetic genes, whereas subcluster II consists of nbtS and nbtT genes. The nocobactin NA BGC is 
deposited in the MIBiG (Minimum Information about a Biosynthetic Gene cluster) database, a 
repository for BGCs linked to its respective natural product.63 It is to mention that subcluster II is not 
deposited in MIBiG. 
 
Figure 4: Model for nocobactin NA biosynthesis. NRPS/PKS domains: adenylation (A), thiolation (T), heterocyclization (Cy), 
condensation (C), epimerization (E), ketosynthase (KS), acyltransferase (AT), ketoreductase (KR). NbtA (type II thioesterase) 
not shown, which presumably rids aberrantly loaded substrates from the PKS or NRPS.4, 64 Adapted from Männle et al..6 
Nocobactin NA biosynthesis commences by loading salicylate, synthesized from chorismate by the 
putative salicylate synthase NbtS and activated by NbtT, onto the ACP domain of NbtF.4 NbtF then 
catalyzes the condensation and heterocyclization of salicylic acid and threonine. Subsequently, NbtD 
condensates lysine with the growing chain. NbtH and NbtG likely direct N-acylation and N-
hydroxylation, respectively. To this point, it is unclear whether this occurs before or after 
incorporation of the lysine moiety. NbtB and NbtC are proposed to activate a fatty acid, which is 
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extended by Claisen-type condensation with methylmalonyl-CoA, subsequently reduced at the β-
position.4 The incorporation of the long chain fatty acyl moiety by ester linkage is probably mediated 
by NbtD before NbtE attaches another lysine. Epimerization of lysine to the D-isomer is followed by 
N-hydroxylation and formation of the ε-caprolactam.65 Based on sequence analysis, NbtA is 
presumed to be a thioesterase type II, which presumably rids aberrantly loaded substrates from the 
PKS or NRPS.4, 64 Interestingly, Hoshino and co-workers state that a ΔnbtE mutant was found to be 
impaired in cytotoxicity against J774A.1 cells, suggesting that nocobactin NA production is required 
for virulence of Nocardia farcinica IFM 10152 similar to mycobactin-conferred virulence in 
Mycobacterium tuberculosis.4, 41, 66 Notably, both structurally and biosynthetically the nocobactins 
closely resemble the mycobactins from Mycobacterium. Consequently, as nocobactin NA has a 
considerable high similarity to this major virulence factor in M. tuberculosis, nocobactins in general 
may have a similar function as virulence factors in Nocardia, contributing to the progression of 
nocardiosis.2, 4 
The biosynthesis of mycobactins has been studied intensively.67-69 Mycobactins and nocobactins 
differ in the position and chain length of their long chain fatty acyl substituents. In mycobactins, fatty 
acyl chains are attached to the N-hydroxylysine moiety whereas nocobactin-like siderophores feature 
N-formylated/N-acetylated N-hydroxylysine residues. Both membrane-bound mycobactins and 
extracellular carboxymycobactins are known to be important for the lifestyle of pathogenic 
Mycobacterium strains and have been shown to play a fundamental role in survival and growth of M. 
tuberculosis in human hosts.55, 66, 70 
  
 
 
 
Introduction 
23 
 
1.3. Bioinformatics for natural product discovery 
1.3.1. Preliminary genomic studies on the genus Nocardia 
In 2014, Komaki and coworkers already analyzed seven Nocardia genomes and found that Nocardia 
strains carry as many PKS-I and NRPS gene clusters as those of Streptomyces strains.2 A hidden 
potential of putative new natural products from a bacterial actinomycete genome can exceed >10% 
of some genomes.71, 72 Furthermore, they state that the number of PKS-I and NRPS BGCs in Nocardia 
strains varies substantially depending on species, with N. brasiliensis strains carrying the largest 
numbers of BGCs.2 Two prevalent pathogens namely Nocardia farcinica IFM 10152 and Nocardia 
brasiliensis HUJEG-1 were analyzed by Komaki and coworkers with a genome size of 6.0 Mb and 9.4 
Mb, respectively. These genome sizes are similar to those of representative Streptomyces strains (5.0 
– 11.9 Mb).2 The authors further suggest that there is no clear relation between genome size and 
pathogenicity in Nocardia strains, presumably, due to their nature as facultative pathogens. In 
comparison, pathogenic Mycobacterium and Rhodococcus strains were found to possess smaller 
genomes, less BGCs, and less diverse BGCs, due to their adaptation to hosts.73, 74 Living inside a host, 
reduces the need to adapt to sudden environmental changes or to fight off microbial competitors, 
reducing the need of different biosynthetic pathways that contributes to genome minimization.75 
Komaki and coworkers highlight Nocardia as highly promising resource in the search of novel 
secondary metabolites.2 Accompanied by the ever increasing amount of publicly available Nocardia 
genome sequencing data, more than 100 Nocardia genomes are now freely available from the 
National Center for Biotechnology Information (NCBI) or the Joint Genome Institute – Integrated 
Microbial Genomes & Microbiomes (JGI-IMG) database, representing a treasure trove for natural 
product discovery.76-81 A recent study on the closely related genus Rhodococcus also emphasizes the 
huge genomic potential of Actinobacteria for secondary metabolite production.82 
1.3.2. Brief history of genome mining 
In the pregenomic era, traditional methods for natural product discovery relied on cultivation of 
bacteria in the laboratory and discovery of novel chemistry was laborious and time consuming. 
Rediscovery of already known natural products was highly likely. Furthermore, due to strict 
regulation mechanisms under standard laboratory conditions, the full secondary metabolite potential 
of a bacterial genome is not reflected. 
Today, genome mining greatly facilitates the prioritization of finding novel chemistry.83 With (next-
generation) genome sequencing on the rise, genomes can be mined for their potential to produce 
secondary metabolites.84 Genome mining has set the foundation for the identification of an 
enormous diversity of natural products even within closely related species.85 It enables researchers 
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to uncover the hidden potential of a genome and facilitates the discovery of novel secondary 
metabolites through computational approaches.83, 86 
Genome mining has revealed that the potential of bacterial genomes goes far beyond what bacteria 
produce under laboratory conditions.87-89 Genes encoding biosynthetic pathways for natural products 
are often organized in BGCs.20, 90, 91 Surprisingly, even well studied strains were found to harbor many 
more BGCs than compounds therefrom discovered.84, 91, 92 However, many BGCs remain 
transcriptionally inactive or ‘silent’ under standard laboratory conditions.93, 94 Doroghazi and 
coworkers recently observed that BGCs from one gene cluster family (GCF) were silent in 77% of their 
strains examined.95 A GCF is defined as a group of BGCs that exhibits similar BGC organization with 
high sequence similarity.96 
1.3.3. Bioinformatic tools for natural product discovery 
It is essential to prioritize and dereplicate putative BGCs bioinformatically, as later rediscovery of 
already known natural products can be frustrating, expensive, and time consuming. Recently, 
suitable genome mining tools have been developed to circumvent rediscovery and to simplify the 
search for new natural products by rapid straightforward detection of secondary metabolite BGCs.97-
100 Currently, the gold standard in genome mining is antiSMASH that allows a rapid genome-wide 
identification, annotation, and analysis of secondary metabolite BGCs in bacterial and fungal 
genomes.1, 98, 101 Several other tools have been developed, such as BAGEL 3, PRISM 3, RODEO, and 
SMURF facilitating genomics based discovery of secondary metabolites.102-105 
The bioinformatics tool BiG-SCAPE is able to read putative BGC GenBank files predicted by 
antiSMASH.3 BiG-SCAPE predicts Pfam composition similarity by hmmscan from the HMMer suite and 
a pairwise distance calculation.106 Pfam is a large collection database of protein families, represented 
by multiple sequence alignments using profile hidden markov models (HMMs).107, 108 A pairwise BGC 
distance matrix is calculated based on a weighted combination of Jaccard Index, Adjacency Index, 
and Domain Sequence Similarity Score. In principle, BiG-SCAPE creates a distance matrix from protein 
domain content, copy numbers, and sequence similarity comparable to a BLAST alignment that can 
be readily imported into sequence similarity networking tools, such as Cytoscape or Gephi.71, 109-111 
Sequence similarity networks (SSNs) have been widely utilized to compare BGCs from large 
sequencing datasets.71, 81, 85, 95 
The MIBiG database can be a valuable repository linking BGCs to their natural products. However, 
MIBiG only links known BGCs to its known compounds. BGCs that have not yet been linked to a 
natural product have been termed ‘orphan’.112 For the purpose of easier linkage of BGCs to 
compounds, a new community-based database called “iOMEGA Paired Data platform” was created 
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(unpublished, personal contribution). The platform links BGCs to tandem mass spectrometry data 
(MS/MS) for structure predictions. Its intention is to link molecules to their producers, find large 
scale genome-metabolome associations, use genomic data to assist in structural elucidation of 
molecules and provide a centralized database for paired datasets. Findings of this thesis are already 
integrated into iOMEGA to contribute and accelerate the field of natural products discovery. 
1.3.4. Challenges of bioinformatic predictions for natural product discovery 
Although genome mining has let to various natural product discoveries to date, its promise of 
revolutionizing natural product discovery has yet to be fulfilled on a large scale, as the process of 
mining genetically encoded natural products is not keeping pace with the rate of genome 
sequencing.96 One of the major bottlenecks in genome mining is that it takes a significant amount of 
time and money to connect a molecule to its biosynthetic signature.96 
Bioinformatic prediction tools such as antiSMASH can be reliably used to predict functions of genes, 
but predictions of new compound classes or chemical structures remain challenging.113 Tools are 
forced with challenges related to the complex and repetitive nature of the biosynthetic genes 
involved and more knowledge about enzymatic functionalities must be generated.95 In addition, 
quality of BGC predictions are highly dependent on quality of the input data, where difficulties can 
arise when genome sequences are highly fragmented or only partial sequences are available.1, 95 
Vice-versa, antiSMASH uses a conservative approach and rather overpredicts BGC borders, resulting 
in hybrid BGCs, consisting of more than one BGC resulting in falsified chemical structure predictions. 
BLAST and Pfam searches for domains in the so-called core genes of polyketide synthase (PKS) and 
nonribosomal peptide synthetase (NRPS) have served as powerful means in identifying BGCs.114 
AntiSMASH predictions, first identify core genes using their conserved motifs and then extends 
predictions to flanking genes encoding tailoring enzymes including hydroxylases, oxidases, 
methylases, transcription factors, and transporter genes. Ziemert and coworkers stated that 
differences in BGCs within a GCF occurred largely among genes predicted to encode tailoring 
enzymes.85 Despite resulting in minor chemical structure differences, it can have a major impact on 
biological activity. As tailoring enzymes are often encoded at distal positions within a BGC and BGC 
border prediction remains challenging, it is often unclear, whether a tailoring enzyme still belongs to 
a BGC, hampering precise chemical structure prediction. Thus, it remains extremely difficult to 
bioinformatically predict the correlation of genetic variability within a GCF in respect to its chemical 
structural diversity. Fortunately, advances in analytical mass spectrometry are revolutionizing the 
ways in which natural products are detected and first attempts were made, linking chemical 
molecular families to respective GCFs of biosynthetic pathways for refined natural product 
discovery.86, 96 
 
 
 
Goals 
26 
 
2. Goals 
This thesis pursues the goal to uncover the biosynthetic potential of the bacterial genus Nocardia by 
application of suitable bioinformatic tools for strain prioritization in natural product discovery. Until 
now, it remains unclear to what extent genetic variability in closely related biosynthetic gene clusters 
relates to chemical structural diversity. Overall, my thesis aims to reveal what adjustments need to 
be made in bioinformatic tools for genetic variability reflection to accurately reflect the chemical 
structural diversity. 
In detail, a comparative genomics to metabolomics approach in the genus Nocardia is conducted by 
evaluating state of the art computational approaches for their application in natural product 
research. The genus Nocardia is examined bioinformatically for its capability to produce novel 
chemistry. In particular, genetic variability in the biosynthetic gene cluster family of nocobactins will 
be highlighted by definition of thresholds in BiG-SCAPE sequence similarity networks to accurately 
reflect the diversity of metal-chelating molecules produced. In cooperation, nocobactin-type 
terpenibactins produced by Nocardia terpenica IFM 0406 will be characterized by MS/MS, NMR, and 
bioassays. Further molecular diversity of nocobactin-like siderophores produced by selected 
Nocardia strains is uncovered by MS/MS and visualized in GNPS (Global Natural Product Social 
Molecular Networking). The resulting chemical structural diversity of this siderophore family is 
utilized to evaluate user-defined BiG-SCAPE thresholds for the prediction of gene cluster families and 
biosynthetic gene cluster subfamilies. Thresholds that most exactly represent genetic variability of 
nocobactin-type BGC subfamilies are identified that best reflect chemical structural diversity of 
nocobactin-type siderophores. 
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3. Results & Discussion 
3.1. Comparative Genomics and Metabolomics in the Genus Nocardia 
3.1.1. Phylogeny and biosynthetic potential of the genus Nocardia 
103 non-redundant Nocardia genomes were downloaded from the NCBI or the JGI-IMG database.76, 
77 In order to assess the evolutionary relationships between Nocardia genomes, a multilocus 
sequence analysis (MLSA) was performed using autoMLST with implemented JSpecies ANI 
analysis.115-117 A maximum likelihood phylogenetic tree was generated with autoMLST that identified 
six major phylogenetic lineages referred to as clades A, B, C, D, E, and F (Figure 5 left). One strain, 
namely Nocardia harenae NBRC 108248 formed a distinct single membered phylogenetic lineage 
referred to as clade X. 
Discrepancies were observed, as two strains, namely Nocardia sp. NRRL S-836 and Nocardia sp. 
348MFTsu5.1 claded with the outgroups such as Rhodococcus erythropolis NBRC 15567. Indeed, 
MASH ANI analysis revealed that these strains belonged to a different genus.118 Estimated average 
nucleotide identity (ANI) values showed a 91.12% ANI closest to Lentzea guizhouensis and 78.91% 
ANI closest to Williamsia muralis NBRC 105860 for Nocardia sp. NRRL S-836 and Nocardia sp. 
348MFTsu5.1, respectively.119 CheckM analysis supported this finding, as both NRRL S-836 and 
348MFTsu5.1 fell into marker lineages others from UID1815 (Nocardia), namely UID1746 and 
UID1814, respectively.120 As the assignment of NRRL S-836 and 348MFTsu5.1 to the genus Nocardia 
was wrong, they were disregarded from further analysis.118, 121 The completeness of all genomes was 
assessed using checkM and revealed a completeness of at least 98.24% with an average number of 
contigs of 147 (1 to 615 contigs per genome). 
The remaining 101 Nocardia strains were isolated from different sources. 50 strains were clinical 
isolates, 31 were derived from environmental sources (freshwater, seawater, or soil), seven were 
isolated from animals, whereas six were found as plant pathogens. All Nocardia genomes were 
analyzed for their biosynthetic capability to produce natural products using antiSMASH that revealed 
a huge diversity of putative BGCs of various classes (Figure 5, right).122 Nocardia showed a high 
putative BGC potential, comparable to the potential of Amycolatopsis and Streptomyces, the latter 
being the most promising producers of natural products to date.74, 123, 124 AntiSMASH revealed an 
average of 34 BGCs per Nocardia genome. This can be compared to the average number of BGCs 
present in the genus Streptomyces, underpinning findings from Komaki and coworkers.2 In 
comparison, the average numbers of BGCs detected in genomes of Micromonospora strains were 20 
BGCs.125  
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Figure 5: Nocardia autoMLST phylogeny and antiSMASH BGC distribution. Maximum likelihood tree of 103 members of 
the genus Nocardia based on 63 concatenated housekeeping genes identified with autoMLST.117 Ultrafast bootstrap values 
were calculated using 1000 replicates. Numbers next to the bars (predicted BGCs by antiSMASH) represent genome sizes in 
Mbp. Average numbers of BGCs per clade are shown. X labels a distinct branch formed by a single Nocardia strain Nocardia 
harenae NBRC 108248. Nocardia genomes marked in red did not contain a nocobactin-like BGC. Adapted from Männle et 
al..6 
Numbers of putative BGCs correlated with clades, where clade A had the highest number of BGCs per 
genome with an average of 48.5 BGCs per genome and where clade C had the least number of BGCs 
per genome with an average of 29.87 BGCs per genome. Most prevalent BGCs in Nocardia were from 
the class of NRPS.74 It can be concluded that Nocardia phylogeny is a more important indicator of 
BGC distribution than geographic origin or source of isolation.85, 123 
A positive correlation was found between numbers of BGCs per strain and respective genome size 
(R2=0.4057; Figure 6). Doroghazi et al. found comparable correlations for selected Actinomycetes 
such as Mycobacterium, Rhodococci, and Streptomyces.82 Larger genomes can accommodate more 
gene clusters devoted to secondary metabolism.82 A similar correlation was also found by Schorn et 
al., where several rare actinobacterial genera were examined for secondary metabolite production.81 
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Figure 6: Number of putative Nocardia BGCs per strain and respective genome size [Mbp]. Genomes were downloaded 
from NCBI or JGI-IMG in *.gbk format. Putative BGCs were predicted with antiSMASH 4.0. Genome size was plotted against 
the number of BGCs. Each dot corresponds to one Nocardia strain. Colors indicate phylogenetic clade A-F and X. Trendline 
indicates a positive correlation between number of BGCs present in a strain and its genome size (coefficient of 
determination (R2=0.4057). Adapted from Männle et al. 2020.6 
When group 1 pathogens (7.6 Mbp; 32.4 BGCs) were compared to the remaining genomes of the 
genus Nocardia (7.8 Mbp; 36.5 BGCs), on average group 1 pathogenic Nocardia genomes were 
smaller and contained less BGCs. N. farcinica IFM 10152, a group 1 pathogen, was found with the 
smallest genome of all Nocardia species analyzed and the least number of BGCs. Surprisingly, this 
finding contradicted results from Komaki and coworkers, who found no clear relation between 
genome size and Nocardia pathogenicity.2 
3.1.2. Metabolic diversity and gene cluster families in Nocardia 
The BiG-SCAPE algorithm was assessed to uncover the diversity of BGCs in the genus Nocardia by 
sequence similarity networks (SSNs). Processed antiSMASH BGCs 101 Nocardia strains were 
incorporated as inputs for BiG-SCAPE.71 SSNs of various thresholds (25-95%) were generated and 
visualized in Cytoscape 3.6.1.109 A Nocardia putative BGC SSN with a threshold of 50% is shown in 
Figure 7A and Figure 8. This 50% SSN consisted of 2836 BGCs as unique nodes that represented single 
putative BGCs from antiSMASH and 22455 edges. In total, the 50% SSN formed 258 independent 
gene cluster families (GCFs) of two or more nodes of varying classes of natural product BGCs. A 
similar threshold of 40% (c = 0.6) was used by Schorn et al. for the definition of GCFs in the analysis 
of rare marine actinomycete genomes.81 
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Figure 7: BiG-SCAPE sequence similarity network (SSN) and nocobactin-like subfamilies visualized in Cytoscape. A: Sequence similarity network (SSN; c = 0.5) of Nocardia spp.. Each node 
represents one BGC identified by antiSMASH 4.0. Colors represent phylogenetic clades A-F and X. Clade-specific GCFs are highlighted. B: SSN (c = 0.3) of nocobactin-like BGCs. Representative 
pathways of different subfamilies (I-IX). Two singletons (X, XI) are shown. TE=thioesterase, KS=ketosynthase, PKS=polyketide synthase, NRPS=non-ribosomal peptide synthetase, NMO=N-
monooxygenase, NAT=N-acetyltransferase, NFT=N-formyltransferase, SHMT=serine hydroxymethyltransferase. Adapted from Männle et al. 2020.6 
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Interestingly, Figure 7A clearly showed a correlation between phylogenetic clades A-F and BGC 
distribution within the SSN. Nocardia strains from clade E encoded a number of BGCs that were 
uniquely found in this clade and were not found elsewhere. This included BGCs for terpenoid, NRPS, 
and PKS pathway biosynthesis. A gene cluster with high similarity to hopene biosynthesis was found 
in all Nocardia of clade E and otherwise only in Nocardia transvalensis NBRC 15921 (clade D).126 In 
contrast, Nocardia spp. from clade F did not form a single characteristic GCF that featured more than 
seven strains. 
Figure 8 showed several large superclusters that consisted of BGCs with different biosynthetic 
features. For example, putative NRPS BGCs (light blue) clustered with putative NRPS-terpene hybrid 
BGCs (white) or putative terpene BGCs (blue). These superclusters could not be satisfyingly resolved, 
even when higher thresholds were applied. Ceniceros et al. reported such problems before and 
attributed them to deficient separation of individual BGCs by antiSMASH input data.74 Hence, a closer 
manual inspection was necessary and revealed a number of distinct subclusters, e.g. GCF 3-6, GCF 9, 
and GCF 10 (Figure 8). In addition, the analysis was repeated with the new BiG-SCAPE “glocal” mode 
option and found no major differences in generated SSNs. In the default “global” mode, all domains 
from both BGCs were taken into account, whereas in the “glocal” mode, only a subset of the domains 
was chosen.3 
GCFs harbored BGCs that were highly abundant in investigated Nocardia genomes (Figure 8). This 
included several GCFs with mono-modular type I PKS-like ketosynthase pathways, e.g. GCF 1, GCF 11, 
and GCF 14, potentially involved in the modification of fatty acid precursors. 
GCF 1 was highly conserved throughout the genus and likely directed the synthesis of mycolic acids. 
Mycolic acids are characteristic and essential cell wall components of Mycobacterium and related 
genera, e.g. Corynebacterium, Rhodococcus, Gordonia, and Nocardia.127 
The lower subcluster of GCF 11 contained BGCs homologous to nocardiolactone (Figure 8). 
Nocardiolactone (Figure 1) is a fatty acid derivative with similarity to lipstatin that has been isolated 
from different Nocardia strains.35 Recently, Robinson et al. reported the identification of the 
nocardiolactone BGC featuring a β-lactone synthetase.128 β-lactone-containing natural products are 
potent inhibitors of diverse hydrolytic enzymes, hence their biosynthesis has drawn a lot of 
attention.129-131 
BGCs from GCF 2 were found in all Nocardia genomes and encoded enzymes for the synthesis of 
ectoine, which stabilizes biopolymers under extreme conditions or osmotic stress.74, 132 In fact, the 
capability to produce ectoine was found in other actinobacterial genera such as Streptomyces, 
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Mycobacterium and in the sister genus Rhodococcus before.133, 134 GCF 3 included pathways highly 
conserved throughout Nocardia which are likely responsible for the formation of carotenoids of 
unknown chemical structure. It encoded polyprenyl synthase (CrtE), phytoene synthase (CrtB), and 
phytoene desaturase (CrtI) homologs for the production of lycopene. An obvious candidate gene 
coding for a lycopene cyclase was not found within BGCs from GCF 3. 
However, a putative lycopene cyclase gene present in all Nocardia species was the main feature of 
the conserved terpene GCF 10. Together, both GCFs could direct the concerted biosynthesis of 
mono- or bicyclic carotenes. Such monocyclic carotenoid glycosides and their esters have been 
isolated from Nocardia kirovani and different Rhodococcus species before.135, 136 Another common 
class of pigments are aryl polyenes, generated by an unusual type II PKS system (GCF 8). These 
molecules are mostly known from Gram-negative γ-Proteobacteria and Bacteroides and are 
widespread in Nocardia (82 of 101 genomes).71 
The gene clusters organized in GCF 4 were found in all Nocardia species and encoded a single NRPS 
with four modules, co-located with a putative N-acyltransferase and two transporters. The produced 
peptide likely consists of an N-terminal serine, three additional amino acids, and presumably feature 
aliphatic or aromatic side chains. 
More conserved NRPS pathways, present in 75 out of 101 Nocardia genomes, were identified in GCF 
5 that consisted of a trimodular NRPS gene with epimerization (E) domains, encoded in the first and 
in the terminal module. 
Similarly conserved were large NRPS assembly lines represented by GCF 6 that always encoded a 
putative nitropropane dioxygenase, a metallopeptidase, an esterase, an epimerase, and an enoyl-
CoA dehydratase. 
Linocin M18 has been described as a secreted bacteriolysin from Brevibacterium linens M18 and has 
been shown to form multimeric microcompartments.137, 138 Respective orthologous BGCs were 
encoded in 103 Nocardia genomes and were summarized in GCF 9. Bacteriolysins were associated 
with pathogen-host cell attachment and immunogenicity in M. tuberculosis and Burkholderia cepacia 
complex.139, 140 
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Figure 8: BiG-SCAPE cluster type sequence similarity network of all BGCs from Nocardia strains found with antiSMASH 
4.0. Colors show cluster types from Nocardia BGCs. Colorless nodes are hybrid BGCs found in Nocardia. Adapted from 
Männle et al. 2020.6 
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3.1.3. The gene cluster family of nocobactins 
Most interestingly, another highly abundant BGC family (GCF 7) was found in 92 of 101 Nocardia 
genomes (Figure 7A, Figure 8). It encoded hybrid PKS/NRPS pathways annotated by antiSMASH as 
putative nocobactin-like BGCs. Over 90% of all Nocardia genomes analyzed encoded such BGCs. This 
widespread occurrence indicated a constitutive role of nocobactins in the biology of the genus. 
Therefore, the genetic variability of the nocobactin-like siderophore GCF 7 was assessed. GCF 7 was 
found to harbor subclusters I of putative nocobactin-type BGCs only, whereas GCF 13 harbored 
subcluster II in cases where a putative nbtF gene was co-located. In Nocardia genomes, nbtF was 
either found on subcluster I or subcluster II, never on both subclusters. AntiSMASH only predicted 
subcluster II, when nbtF was co-located with cluster II and falsely termed it as a putative mycobactin-
like BGC. Otherwise, subcluster II was completely absent from the analysis. A manual concatenation 
of subcluster I and subcluster II and reanalysis via BiG-SCAPE did not change the nocobactin-like GCFs 
at a threshold of 70%. The splitting of the nocobactin-type BGCs into subclusters I and II was 
reflected in the 50% BiG-SCAPE SSN. In Figure 8, GCF 7 represented nocobactin-type subcluster I, 
whereas GCF 13 represented nocobactin-type subcluster II. Interestingly, GCF 13 was annotated by 
antiSMASH as a putative mycobactin-like BGC with 30% similarity. GCF 13 contained a small pathway 
of three conserved genes with homology to nbtF, nbtS, and nbtT. These genomes lacked a nbtF-like 
gene in their respective nocobactin-like subclusters I and nbtF in subcluster II was not only a copy 
thereof. However, subcluster II was only recognized bioinformatically, when nbtF was co-located 
with nbtS and nbtT. This BGC organization was found to be shared by almost 45% of Nocardia strains 
analyzed. 
The nocobactin family GCF 7 in Figure 8A formed two distinct subareas at a threshold of 50% that 
pointed out genetic differences. Indeed, each subarea was characterized by the exclusive presence of 
either a gene for an N-acetyltransferase (NbtH homolog) or an N-formyltransferase (TerH homolog), 
suggesting that the subdivision of the nocobactin family GCF 7 reflected the production of 
structurally different derivatives. These derivatives suggested either an acetyl or a formyl group 
attached to the N-hydroxylysine residue. 
To further refine the putative nocobactin-like GCF 7 from the BiG-SCAPE 50% threshold SSN, a 
threshold of 70% was applied (Figure 8B). This resulted in the segmentation of GCF 7 into nine 
independent families of more than two BGCs (referred to as nocobactin-like BGC subfamilies I-IX) and 
two singletons (X and XI). Interestingly, nocobactin-like BGC subfamilies correlated with the 
phylogenetic clades observed by autoMLST analysis. Subfamilies II, V, VIII, and IX consisted solely of 
pathways from clade E, B, C, and F, respectively. Subfamilies I and VII were dominated by clades D, F, 
and A, B, respectively. Presence or absence of nbtH/terH homologous genes also determined these 
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subfamilies at a threshold of 70% by means of subfamilies I and III that encoded a nbtH homologous 
gene, whereas subfamilies II, IV, and VI-IX encoded a gene homologous to terH. Only subfamily V 
comprised pathways that harbored both nbtH and terH homologous genes. In addition, splitting of 
subfamilies was based on the presence/absence of the nbtF homolog in subcluster I. Subfamilies II, 
III, VI-VIII, and IX encoded a putative nbtF gene in subcluster I, whereas in strains of subfamilies I, IV, 
and V, a putative nbtF gene was found to be present in subcluster II. 
Further characteristic features of GCF 7 were additional NRPS modules in subfamilies II, VI, VIII, and 
IX. Here, the nocobactin-like pathways encoded a discrete C-T didomain protein, probably a 
functional substitute to the missing terminal C-T domains of the NbtD homolog and another NRPS 
enzyme with a C-A-T-E-C domain structure. Unfortunately, it was not possible to predict the 
specificity of the corresponding A-domain bioinformatically. 
Known nocobactin-type molecules showed diversity in stereochemical configurations. Nocobactin NA 
features a central N-acylated N-hydroxy-L-lysine and a terminal N-hydroxy-D-lysine-1,6-lactam. In 
contrast, amamistatin A incorporates D- and L-lysine and brasilibactin A D- and D-lysine derivatives at 
these positions, respectively.4, 49, 52 It was likely that the presence of additional epimerization (E) 
domain-containing NRPS-enzymes found in subfamilies II (including N. terpenica IFM 0406), VI, VIII, 
and IX might produce different stereoisomers. Exemplary, the NRPS TerE from N. terpenica IFM 0406 
epimerizes and condensates a N-hydroxylysine, which is subsequently lactamized, most likely in a 
non-enzymatic way.65 
Moreover, in subfamilies VI and VIII the PKS enzymes with homology to NbtC were extended by a C-
methyltransferase domain to an AT-KR-T-cMT module with predicted AT-domain specificity to mmal-
CoA. Notably, formobactin A and the amamistatins contain a rare α-dimethylated fatty acid which 
could derive from such a biosynthetic set-up. 
The co-localization of a gene for a putative SagB-type dehydrogenase was characteristic for the 
clusters subsumed in subfamilies I, III, V, and VII. Furthermore, the subfamilies were distinguished 
based on transporter location likely associated with the BGCs. In subfamilies II, IV, VI, VIII, and IX, 
transporters were located within nocobactin-type BGCs, whereas in subfamilies I, III, V, and VII, 
transporters were located immediately adjacent to the clusters. 
In total, nine nocobactin-type BGCs appeared as singletons in the BiG-SCAPE SSN with a threshold of 
70% and did not cluster with other BGCs from previously defined subfamilies. Their nocobactin-type 
BGC architecture looked different from other nocobactin-type BGCs, e.g. by means of gene 
duplication. N. fusca NBRC 14340 encoded one of these unique pathways and appeared as the only 
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strain with a nocobactin-type BGC in subfamily X. This BGC contained homologs to all genes of the 
nocobactin NA gene cluster with an additional copy of nbtF, a terH-like gene that coded for a 
putative N-acetyltransferase, a nbtH-like gene that coded for a putative N-formyltransferase, a gene 
for a discrete A domain and a putative serine hydroxymethyltransferase gene with a 59% sequence 
identity on protein level to FmoH from Streptomyces sp. Sp080513GE-23. Interestingly, as FmoH 
serves as a biosynthetic precursor for an unusual 4-methyloxazoline moiety, such a moiety was also 
found in the mycobactin-type siderophore BE-32030 produced by Nocardia sp. A32030.53, 141 
Furthermore, Nocardia vermiculata NBRC 100427 (subfamily XI) showed two copies of an nbtABC-like 
operon and encoded nbtD-, nbtG-, and terH-like genes together with an additional NRPS module and 
transporters at another independent location on the genome different from subcluster I or II. 
3.1.4. Nocobactin-type siderophores produced by selected Nocardia strains 
In order to verify the BiG-SCAPE nocobactin-type subfamilies, representative Nocardia strains were 
ordered that encoded pathways with characteristic biosynthetic functionalities. For this purpose, 
selected Nocardia strains were cultivated under iron limiting conditions and intracellular membrane-
associated culture extracts were subjected to positive ion mode LC-MS analysis. Extracts were 
treated with gallium sulfate (Ga2(SO4)3) under reducing conditions to stabilize metal-chelating 
nocobactin-type siderophores and to simplify MS identification via their distinct gallium isotopic 
pattern. Metal-free siderophores and Fe3+-bound nocobactin-type siderophores were largely 
replaced by Ga3+. 
MS/MS spectra of twelve Nocardia strains and pure samples of terpenibactins A-C were used to 
construct molecular networks with GNPS visualized in Cytoscape.5, 109 This resulted in a molecular 
network of ionizable metabolites with 3567 nodes and 4177 edges (Figure 9). At a cosine value of 0.6, 
the GNPS network formed 108 clusters of two or more nodes and showed 2470 singletons. The 
terpenibactins clustered with one molecular family from seven Nocardia strains that likely 
represented molecular families of compounds with similar chemical structures (Figure 9a). Each of 
these seven Nocardia strains produced a variety of different nocobactin-type siderophores with 
varying fatty acyl chain length and saturation that clustered with the terpenibactins. N-hydroxylysine 
N-acetylation or N-formylation, as well as oxazole or oxazoline moieties were consistently present. 
Exemplary, one postulated nocobactin-type siderophore is shown per nocobactin-type BGC subfamily 
(Figure 10). 
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Figure 9: Global Natural Product Social Molecular Networking (GNPS) MS/MS network of culture extracts from selected 
Nocardia strains. Node color indicates the source strain of each ion. Bold node borders indicate putative 
carboxynocobactins. Molecular families a and b containing putative siderophores are highlighted by gray framed boxes. 
Medium was prepared after Ratledge et. al..142 Adapted from Männle et al. 2020.6 
These nocobactin-type siderophores from seven different Nocardia strains represented molecules 
with minor structural differences to published nocobactin NA. All MS/MS predicted siderophores 
from N. alba NBRC 108234 (subfamily I), N. elegans NBRC 108235 (subfamily II), N. cyriacigeorgica 
GUH-2 (subfamily VI), N. gamkensis NBRC 108242 (subfamily VII), N. rhamnosiphila NBRC 108938 
(subfamily VIII), N. jejuensis NBRC 103114 (subfamily IX), N. fusca NBRC 14340 (subfamily X), and N. 
vermiculata NBRC 100427 (subfamily XI), as well as the known compounds from literature produced 
by N. farcinica IFM 10152 (subfamily III) and the previously reported siderophores from N. terpenica 
IFM 0406 (subfamily IV), all included a phenoxazoline/-oxazole, an N-acylated N-hydroxylysine, a 
hydroxy fatty acid, and a ε-caprolactam moiety.4, 7 This core structure was independent of the BGC 
composition by means of presence of additional NRPS genes (subfamilies II, VI, VIII, and IX), 
duplication of PKS genes (subfamily XI) or absence of the nbtF homologous gene in subcluster I 
(subfamilies I, IV, V, and X). 
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Figure 10: nocobactin-type siderophores produced by selected Nocardia strains from subfamilies I – XI. Selected 
representative compounds from each subfamily are shown. Structures shown in I, II, and VI-XI subfamilies were predicted 
from high resolution MS/MS experiments. Adapted from Männle et al. 2020.6 *chemical structure shown have been 
adopted from Hoshino et al. and Chen et al..4, 7 
The presence of NbtH and TerH homologs, as well as PKS C-methyltransferase domains within 
nocobactin-type BGCs was reflected in MS/MS fragmentation patterns of the identified nocobactin-
type molecules. In accordance with bioinformatic predictions, pathways from subfamilies I, III, and V 
produced N-acetylated and pathways from subfamilies II, IV, VI, VII, and VIII-IX produced N-
formylated nocobactin derivatives. Furthermore, colocation of a sagB-type dehydrogenase gene with 
nocobactin-type BGCs in subfamilies I, III, and VII led to the production of nocobactin derivatives with 
a phenoxazole moiety. Vice-versa, the absence of a sagB-type dehydrogenase gene in subfamilies II, 
IV, VI, and VIII-XI correlated with the production of phenoxazoline moiety containing nocobactin 
derivatives. This indicated that this SagB-type dehydrogenase was involved in the oxidation of the 
oxazoline ring in nocobactin-type siderophore biosynthesis. 
Interestingly, MS/MS structure predictions suggested that N. alba NBRC 108234 (subfamily I) 
produced nocobactin-type siderophores with a non-methylated oxazole moiety and an N-acetyl 
group that matched nocardimicin A, B, and D (Figure 10). Additionally, N. elegans NBRC 108235 
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(subfamily II) and N. jejuensis NBRC 103114 (subfamily IX) produced N-formylated, non-methylated 
oxazoline-containing molecules that matched chemical structures of nocardimicin G and 
nocardimicin H, respectively. Extracts of N. cyriacigeorgica GUH-2 (subfamily VI) were analyzed and 
an ion was found that matched the MS/MS predictions for brasilibactin A.50. Additionally, the 
nocobactin-type BGC from N. gamkensis NBRC 108242 (subfamily VII) revealed a compound that 
matched formobactin.51 Notably, N. rhamnosiphila NBRC 108938 (subfamily VIII) produced a 
molecule likely containing a non-methylated oxazoline, an N-formyl group, and a gem-dimethylated 
hydroxy fatty acid moiety that was not described before. 
In order to determine the correct position of the methylene unit in fragment ions of the nocobactin-
type siderophore from N. alba NBRC 108234, 13C1-L-serine was fed, and culture extracts were 
analyzed by LC-MS. A characteristic shift indicated the incorporation of 13C1-L-serine into the 
oxazoline ring that indicated the presence of an N-acetyl group. For the biosynthesis of mycobactin, 
it has been proposed that the oxazoline ring derives from demethylation of a methyloxazoline 
moiety.143 For nocobactin-type siderophores in Nocardia spp., data suggested that methylation of the 
oxazoline ring rather depended on the specificity of the respective A-domain towards serine or 
threonine in the NbtF homolog. 
In particular, two metabolites identified from N. gamkensis NBRC 108242 caught my attention. Exact 
masses indicated modification of the central hydroxy fatty acyl unit by an additional carboxylic acid 
group. In analogy to carboxymycobactins, these two molecules may represent similarly oxidized 
“carboxynocobactins”.55, 144 It was assumed that missing genes for carboxynocobactin-type 
siderophore production (e.g. carboxylase genes) were located on another genomic region. 
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3.1.5. Identification of a mycobactin-type siderophore 
Interestingly, MS/MS spectra from N. araoensis NBRC 100135 (subfamily III) and N. takedensis NBRC 
100417 (subfamily VII) correlated with mycobactin-type siderophores with the long fatty acyl moiety 
attached to the N-hydroxylysine side chain. In order to verify mycobactin-type siderophore 
production, a compound from culture extracts of N. araoensis NBRC 100135 was isolated. NMR 
structural assignments of the gallium-bound siderophore identified key spin systems that revealed 
that the fatty acid indeed was attached to the linear N-hydroxylysine side chain (Figure 11). As NBRC 
100135 and NBRC 100417 were genuine representatives of their respective subfamilies and no 
mycobactin-type BGCs were found on respective genomes, it was difficult to explain why they 
produced mycobactins instead of nocobactins. It was speculated for mycobactin biosynthesis in 
Nocardia spp. that in trans-encoded enzymes were recruited from other metabolic pathways that 
encoded a long-chain fatty acid N-acyltransferase. 
 
Figure 11: TOCSY correlations and key HMBC correlations of a mycobactin-type siderophore with m/z 840.3669 [M+Ga-
2H]+. Adapted from Männle et al. 2020.6 
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3.2. New Nocobactin Derivatives with Antimuscarinic Activity, 
Terpenibactins A-C, Revealed by Genome Mining of Nocardia 
terpenica IFM 0406 
3.2.1. Identification and organization of the terpenibactin BGC 
Genome mining of Nocardia terpenica IFM 0406 using antiSMASH revealed the presence of 38 BGCs 
including a split BGC (separated by 282 kbp) with predicted high similarity to the nocobactin NA-a 
and NA-b BGC from Nocardia farcinica IFM 10152 (termed as subcluster I and subcluster II) (Figure 
12). From now on it will be termed terpenibactin BGC.98 The requisite genetic machinery for 
nocobactin biosynthesis was present. However, within the terpenibactin BGC, a nbtH-like gene was 
missing. In Nocardia farcinica IFM 10152 nbtH encoded a N-hydroxylysine N-acetyltransferase. 
Instead, the terpenibactin BGC encoded a N-hydroxylysine N-formyltransferase gene in place of 
nbtH, termed terH (Figure 12).7 
 
Figure 12: Comparison of the nocobactin NA biosynthetic gene cluster (top, Nocardia farcinica IFM 10152) with a novel 
BGC (bottom, Nocardia terpenica IFM 0406). Blue shading links homologous genes. After Chen et al..7 
Additionally, the terpenibactin BGC encoded a homologous gene to nbtF (termed terF) in subcluster II 
together with nbtS- and nbtT-like genes (termed terS and terT), whereas respective terF gene was 
absent in subcluster I. In Nocardia farcinica IFM 10152, nbtF was located at the first locus. The 
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relocation of the nbtF-like gene in Nocardia terpenica IFM 0406 did not preclude the production of 
new nocobactin congeners, since in nocobactin biosynthesis, NbtF acts directly after NbtS and NbtT, 
which are also located at locus two.4 The resultant biosynthesis of terpenibactins A-C was analogous 
to the delineated biosynthesis of nocobactin NA with exceptions addressed to presence of a terH 
gene and absence of a putative SagB-type dehydrogenase in the terpenibactin BGC.4 SagB is involved 
in the biosynthesis of streptolysin S toxin by catalyzing the oxidation of oxazoline and thiazoline 
heterocycles to form oxazole and thiazole ring structures.145 
Since terpenibactin biosynthesis involved the utilization of fatty acids derived from primary 
metabolism, it was challenging to predict the lengths of acyl chains by bioinformatics. Considering 
the range of known nocobactin-type compounds, chain lengths were assumed between C7-C17 units 
long. From bioinformatics predictions, one or more brasilibactin-type compounds were postulated 
and masses between 701 and 841 Da were suggested. 
Stereochemical predictions of the absolute configuration of the amino acid-related moieties were 
conducted on the basis of in silico predictions from the terpenibactin BGC. The E domain in TerE 
indicated the conversion of the activated lysine into the D-configuration, whereas absence of C/E and 
E domains in TerF and TerD suggested the incorporation and processing of L-configured threonine 
and lysine moieties. This suggested an R configuration at position 1 and S configurations at positions 
12, 14 and 15 (Figure 17). 
3.2.2. LC/MS screening for the products of the terpenibactin BGC 
Nocardia terpenica IFM 0406 cell pellet methanol extracts were generated as reported before for 
nocobactin NA and similar compounds.44, 47-50 Extract MS analysis led to the detection of three peaks 
in the sought-after mass range, with UV spectra maxima at 219, 255, and 339 nm as expected from 
nocobactin NA UV profiles indicative of a substituted benzenoid chromophore with an extended 
conjugated system. All three peaks absorbed at 460 nm when analyzed via HPLC, as would be 
expected of Fe3+-siderophore complexes similar to Fe3+-nocobactin NA (Figure 13).44 In total, each 
compound was detected as single charged pseudo-molecular ion [M+H]+, ferrated form [M-
3H+Fe3++H]+, and sodium adduct [M-3H+Fe3++Na]+. As MS data did not match any known compound, 
new nocobactin-type siderophores were termed terpenibactins A-C named after the producing strain 
Nocardia terpenica IFM 0406 (Figure 14). 
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Figure 13: Terpenibactins A-C HPLC profile. Terpenibactins appeared between 16-18 min at 460 nm in HLPC. After Chen.146 
 
Figure 14: free terpenibactins A-C (left) and ferrated terpenibactins A-C (right) produced by Nocardia terpenica IFM 0406. 
All attempts for the decomplexation of ferric nocobactin after Ratledge and Snow failed.44 As a 
consequence, extracts were treated with Ga2(SO4)3 to generate stable complexes, even facilitating 
high-quality NMR measurements.61, 147, 148 This method simplified MS analysis of culture extracts, due 
to the characteristic gallium isotope pattern of gallium-complexed siderophores. Fragmentation 
patterns of Ga2(SO4)3 treated terpenibactins A-C were consistent along the ester linkage between the 
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modified lysine residue and the β-hydroxy fatty acid moiety. After removal of the ε-caprolactam, 
gallium-bound substructures remained as a bidentate ligand and produced characteristic fragment 
ions for terpenibactin A (Figure 15). Further characteristic fragment ions observed represent the ε-
caprolactam moiety. In analogy, similar fragmentation patterns were observed for terpenibactin B 
and C with fragment ions that stemmed from a slightly different fatty acyl moiety (Figure 16). 
 
Figure 15: MS/MS fragmentation pattern of gallium-bound terpenibactin A. Precursor mass (m/z 882.4135 [M-2H+Ga]+) is 
marked with a blue diamond. 
N-formylation of the N-hydroxylysine residue in terpenibactin biosynthesis was postulated 
bioinformatically according to presence of terH within the terpenibactin BGC instead of presence of a 
gene homologous to nbtH. Brasilibactin A (isolated from Nocardia terpenica IFM 0995) also featured 
a N-formylated N-hydroxylysine residue.50 Additionally, absence of a putative SagB-type 
dehydrogenase encoded within the terpenibactin BGC was characteristic for oxazoline ring 
formation. According to findings from Männle et al., a methylated oxazoline ring was the only 
plausible structure prediction in accordance with the terpenibactin BGC.6 Furthermore, MS/MS 
fragmentation spectra showed fragments common to terpenibactins A-C, namely those of the ε-
caprolactam ring with the neighboring amide group alone and with the full amide bond (Figure 15). 
Predictions of their exact masses closely matched observed masses for terpenibactin A, B, and C 
found with high resolution MS (Table 1). In total, MS/MS analysis confirmed the nocobactin-like 
structure of terpenibactins A-C (Figure 16). 
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Table 1: Terpenibactin A, B, and C produced by Nocardia terpenica IFM 0406. 
 
 
Figure 16: Chemical structures and chemical formulae of gallium-bound terpenibactins A-C. Gallium-bound terpenibactin 
A (m/z 882.41383 [M-2H+Ga]+), gallium-bound terpenibactin B (m/z 908.42948 [M-2H+Ga]+), and gallium-bound 
terpenibactin C (m/z 910.44513 [M-2H+Ga]+). 
3.2.3. NMR structure elucidation of terpenibactins A-C 
1H and 13C NMR spectra suggested compounds similar to nocobactin NA with aromatic protons and a 
singlet attributed to a formyl group. The N-formyl-N-hydroxylysine substructure was determined by 
COSY and confirmed by NOESY correlations (Figure 17Error! Reference source not found.). F
urthermore, terpenibactin A 13C NMR spectra showed signals that gave rise to a methylated 
oxazoline. 1H-1H COSY and 1H-13C HSQC NMR analysis revealed that signals observed in 13C NMR 
belonged to a spin system including a methyl group (Figure 17). To confirm unsaturation in the 
extended alkyl chains of terpenibactin B, further COSY/HSQC-TOCSY correlations were elucidated 
(Figure 17). The precise location of this double bond was proposed through HSQC-TOCSY NMR and 
suggested that the double bond occurred between carbons at positions 31 and 32. The terpenibactin 
A-C ε-caprolactam ring common with nocobactin NA was confirmed by COSY and HSQC-TOCSY NMR 
correlations (Figure 17). COSY NMR confirmed a 2-methyl-3-hydroxyoctadecanoic moiety in 
terpenibactin A by COSY correlations (Figure 17). Further COSY correlations between methane 
carbon 8 and 10 also confirmed the presence of the 2-methyl-3-hydroxyoctadecanoic moiety. All 
three methane carbons at positions 8, 9, and 10 in turn showed HMBC correlations with the carbonyl 
carbon at position 7. COSY correlations were found to link the carbon at position 10 with carbons 29 
to 31, and carbon 42 with a terminal methyl group at position 43. A precise listing of all 
terpenibactins A-C chemical shifts is shown in Table 2. 
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Table 2: 1H and 13C NMR spectroscopic table for terpenibactins A-C. Measured at 400 MHz (1H) and 100 MHz (13C) in d4-
MeOH). After Chen.146 
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Figure 17: Proposed structure of terpenibactin A. Bold bonds show COSY/HSQC-TOCSY correlations; red arrows show 
HMBC correlations; blue arrows show NOESY correlations. Terpenibactin C has the same structure with a fatty acid chain 
extended by 2 x CH2 units. Terpenibactin B shows COSY/HSQC-TOCSY correlations from positions 29 to 33, including a 
double bond between position 31 and 32. In silico predictions of the incorporations of D-lysine, L-lysine, and L-threonine 
into the terpenibactin backbone resulted in a relative stereochemistry of 1R, 12S, 14S, and 15S. After Chen.146 
3.2.4. Biological properties of terpenibactins A-C 
Gallium-chelated terpenibactins A-C were evaluated in antimicrobial, cytotoxic, and muscarinic M3 
receptor calcium flux assays (Table 3). In antimicrobial assays, terpenibactins A-C were inactive at an 
MIC level of 64 µg/mL. In cytotoxicity assays, terpenibactins A-C showed moderate bioactivity. 
However, Sakagami et al. demonstrated that iron-chelated nocobactins exhibit cytotoxic activity two 
orders lower than its corresponding iron-free form.45 It is possible that gallium-chelated 
terpenibactins were affected similarly. All three compounds showed potent muscarinic M3 receptor 
inhibitory activity. These findings were in good agreement with IC50 values reported from 
nocardimicins A-H (0.37 to 5.89 µM).47, 48  
Table 3: Biological activities of terpenibactins A-C. Modified after Chen et al..7 
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4. Conclusion & Outlook 
The computational investigation of the prolific genus Nocardia revealed valuable insights into its 
highly diverse biosynthetic capacity to produce natural products. The longstanding question of the 
relationship of BGC genetic variability within GCFs and chemical structural diversity was addressed by 
relation of observed nocobactin-type BGC variation to respective predicted nocobactin-type 
siderophore diversity by chemical analytics data. 
In conclusion, antiSMASH with subsequent BiG-SCAPE SSN analysis were shown to be suitable 
bioinformatic tools to successfully predict Nocardia GCFs (50% threshold) and BGC subfamilies (70% 
threshold for nocobactins) on a large scale. Comparative genomics data was successfully linked to 
respective chemical analytics data for refined chemical structure prediction of nocobactins. Observed 
Nocardia nocobactin-type siderophore chemical structural variations predicted by MS/MS matched 
distinct nocobactin-type BGC subfamilies at a 70% threshold. Thus, Nocardia nocobactin-type BGC 
genetic variability between strains indeed was reflected as chemically diverse nocobactin-type 
siderophores. It was shown that substitution of single biosynthetic genes, e.g. N-formyltransferase 
instead of a N-acetyltransferase gene, lead to distinct chemical structure. I was able to describe new 
nocobactin variants, new carboxynocobactins, and mycobactin variants from several Nocardia 
species. No BGCs were reported before that were associated with the siderophores brasilibactin A, 
nocardimicins A-I, and formobactin. Chemical structures of three new nocobactin-type siderophores 
and one mycobactin-type siderophore, were elucidated using NMR. In particular, the terpenibactins 
were found to possess inhibitory activity to the muscarinic M3 receptor, while exhibiting only a low 
cytotoxicity, providing suggestions for beneficial medical applications. 
In summary, the use of SSNs allowed the distinction and prediction of natural product structural 
variations in the genus Nocardia. The putative BGC potential per genome of Nocardia indeed rivals 
better investigated genera such as Streptomyces and Amycolatopsis.74, 123, 124 Some GCFs were 
widespread throughout Nocardia, raising questions about their role in nature. One such GCF encoded 
nocobactin-type siderophores that might play a similar role in virulence, as mycobactins do in 
Mycobacterium. First evidence for nocobactins as virulence factors in Nocardia was already provided 
by Hoshino et al., but further confirmation is needed.4 As a vast majority of BGCs from Nocardia were 
orphan and were not associated with a discovered natural product so far, results from this thesis will 
facilitate future genome mining approaches and lower the chance of natural product rediscovery by 
prioritizing Nocardia BGCs and strains for a future genomics-driven targeted exploitation of the 
genus Nocardia for natural product drug discovery campaigns, biomedical applications, or the 
chemical industry. 
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Bradley S. Moore,e,f Nadine Ziemert,b,c Leonard Kayssera,b
aPharmaceutical Biology, Eberhard Karls University Tübingen, Tübingen, Germany
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ABSTRACT Using automated genome analysis tools, it is often unclear to what de-
gree genetic variability in homologous biosynthetic pathways relates to structural
variation. This hampers strain prioritization and compound identification and can
lead to overinterpretation of chemical diversity. Here, we assessed the metabolic po-
tential of Nocardia, an underinvestigated actinobacterial genus that is known to
comprise opportunistic human pathogens. Our analysis revealed a plethora of puta-
tive biosynthetic gene clusters of various classes, including polyketide, nonribosomal
peptide, and terpenoid pathways. Furthermore, we used the highly conserved bio-
synthetic pathway for nocobactin-like siderophores to investigate how gene cluster
differences correlate to structural differences in the produced compounds. Sequence
similarity networks generated by BiG-SCAPE (Biosynthetic Gene Similarity Clustering
and Prospecting Engine) showed the presence of several distinct gene cluster fami-
lies. Metabolic profiling of selected Nocardia strains using liquid chromatography-
mass spectrometry (LC-MS) metabolomics data, nuclear magnetic resonance (NMR)
spectroscopy, and GNPS (Global Natural Product Social molecular networking) re-
vealed that nocobactin-like biosynthetic gene cluster (BGC) families above a BiG-
SCAPE threshold of 70% can be assigned to distinct structural types of nocobactin-
like siderophores.
IMPORTANCE Our work emphasizes that Nocardia represent a prolific source for
natural products rivaling better-characterized genera such as Streptomyces or Amycola-
topsis. Furthermore, we showed that large-scale analysis of biosynthetic gene clusters us-
ing similarity networks with high stringency allows the distinction and prediction of
natural product structural variations. This will facilitate future genomics-driven drug
discovery campaigns.
KEYWORDS Nocardia, biosynthetic gene cluster, genome mining, genomics,
metabolomics, natural products, siderophores
Bacterial natural products are an important source for small-molecule pharmaceu-tics. Historically, they have played a major role in what is arguably the greatest
success story of modern medicine: the containment of microbial infectious diseases.
Nowadays, natural products still represent frequently used lead structures for the
development of antibiotic, anticancer, and immunosuppressive agents (1). However,
over the last decades, the pharmaceutical industry has shown dwindling interest in
classic natural product screening programs. This is primarily due to the increasing
rediscovery rate of already known molecules especially in well-investigated bacterial
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genera such as Streptomyces. In recent years, several developments have revived
interest in microorganisms as a source of new drug leads. On the one hand, underin-
vestigated bacterial taxa were shown to comprise prolific producers of novel bioactive
chemistry (2). On the other hand, genome sequencing revealed that even in extensively
studied bacteria, the molecules isolated so far represent only the tip of the iceberg (3).
The biosynthetic capacity of filamentous actinobacteria, such as Streptomyces, and
myxobacteria, cyanobacteria, and many others, often exceeds 30 or more predicted
secondary metabolites per strain. Notably, most of these orphan pathways cannot be
associated with known compounds, making them a formidable source for new chem-
istry and drug leads. However, with more than 400,000 putative gene clusters in the
database of the Joint Genome Institute (JGI), the development of bioinformatic tools to
assess and prioritize these pathways has become crucial (4). For this purpose, a number
of different web-based genome analysis platforms have been established allowing
gene-to-molecule predictions of varying accuracy (5). Firm knowledge of the limitations
of such approaches is of critical importance to evaluate the novelty of encoded
compounds with sufficient confidence.
Here, we explore the potential of the genus Nocardia for the biosynthesis of natural
products. Moreover, we use the highly conserved nocobactin pathway to probe
thresholds and limits of popular gene cluster analysis tools. Nocardia are rod-shaped
partially acid-fast actinobacteria of the order Corynebacteriales, closely related to Rho-
dococcus, Corynebacterium, and Mycobacterium. They are able to form branching,
filamentous mycelia that can fragment into bacteroid nonmotile elements. Nocardia are
ubiquitous saprophytes often found in organic-rich soil, but they are most prominently
known as opportunistic pathogens. Nocardiosis is an infectious disease affecting the
immunocompromised with a high mortality rate, but it has also been reported for
immunocompetent patients (6). Commonly, Nocardia cause localized cutaneous or
pulmonary infections depending on the nature of exposure to the pathogen. From
here, the bacteria may disseminate, leading to systemic forms of nocardiosis and severe
brain infections. The pathogenicity of Nocardia has been extensively studied by Bea-
man and others (7). Still, major aspects are poorly understood, including the role of
virulence factors in strain-specific development and characteristics of the disease. Over
the last decades, Nocardia have also served as the occasional source for natural
products (Fig. 1) (8–11). However, in comparison to other genera of the phylum, the
chemistry of Nocardia is vastly underexplored. Notably, the preliminary analysis of the
first seven available Nocardia genomes by Komaki et al. in 2014 showed a diverse
repertoire of nonribosomal peptide synthetase (NRPS) and type I polyketide synthase
(PKS) pathways (12). The authors found that the content of respective gene clusters
varies considerably between different clinically relevant Nocardia pathogens, ranging
from 12 such pathways in Nocardia farcinica IFM 10152 to 30 in some investigated
Nocardia brasiliensis strains (IFM 10847 and HUJEG-1). NRPS and type I PKS are multi-
modular biosynthetic machineries in which every module is responsible for the incor-
poration of a building block by assembly line logic. They are important driving forces
for the generation of chemical diversity and structural complexity in bacterial natural
products. Other relevant classes of secondary metabolites include type II and type III
polyketides, terpenoids, ribosomally synthesized and posttranslationally modified pep-
tides (RiPPs), alkaloids, and nucleosides. In the current report, we present a compre-
hensive analysis of the biosynthetic capacity of the genus Nocardia based on 103
published genomes. To this end, we used an integrated workflow that combines the
most popular gene cluster analysis tool antiSMASH and the recently developed BiG-
SCAPE algorithm to generate sequence similarity networks (13, 14). With this setup, we
observed tremendous potential for the production of bioactive small molecules rivaling
Streptomyces in number and diversity. Several biosynthetic pathways were found to be
conserved throughout the genus including a gene cluster for the formation of
nocobactin-type siderophores. Using this pathway as a proxy, we probed different
stringencies to construct the sequence similarity networks and correlated the gener-
ated gene cluster families (GCFs) with a mass spectrometry (MS) metabolic network.
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Strikingly, by applying a BiG-SCAPE threshold of 70%, we were able to produce GCFs
that could be assigned to the synthesis of structurally distinct groups of nocobactin
derivatives.
RESULTS AND DISCUSSION
Phylogeny and biosynthetic potential of the genus Nocardia. A search in public
databases such as NCBI and JGI found 103 nonredundant genome sequences from
organisms named Nocardia, as of 2017. The genomes had an average of 147 contigs (1
to 615) with an estimated completeness of at least 98.24%, as analyzed by checkM (see
Table S20 at https://doi.org/10.5281/zenodo.3784407). In order to obtain an overview
about the diversity of the genus and evolutionary relationships within the genus, we
built phylogenetic trees using the web tool autoMLST (15). To this end, 63 conserved
housekeeping genes with neutral dN/dS (ratio of nonsynonymous to synonymous
evolutionary changes) values were identified by autoMLST and used for the concate-
nated alignment as a basis for tree building. The resulting tree (Fig. 2) shows six major
clades (A to F) within the genus and one distinct branch (X) formed by the single strain
Nocardia harenae NBRC 108248. Interestingly, two strains formed a clade outside the
outgroups, indicating that they do not belong to the genus Nocardia. MASH analysis
(16) to estimate the average nucleotide identity (ANI) showed that both strains, named
Nocardia sp. strain NRRL S-836 and Nocardia sp. strain 348MFTsu5.1, are more similar to
Lentzea guizhouensis and Williamsia muralis NBRC 105860 with an ANI of 91.12% and
78.91%, respectively, thus providing further evidence that these strains are incorrectly
assigned and do not belong to the genus Nocardia (17). Furthermore, these results were
supported by checkM analysis, as both strains fall into different lineage markers. We
therefore did not include these two strains in further analysis. From the 101 remaining
analyzed Nocardia strains, 50 are clinical isolates, seven have been isolated as animal
and seven as plant pathogens, and 31 are derived from environmental sources.
FIG 1 Selected known and predicted compounds from Nocardia spp.
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Nocardia of all origins are evenly spread across the six phylogenetic clades, suggesting
that pathogenicity of Nocardia strains is not reflected by evolutionary relationship (see
Fig. S30 at https://doi.org/10.5281/zenodo.3784407). To assess the biosynthetic poten-
tial of the strains, we performed computational genome mining analysis using the
program antiSMASH (13). All analyzed genomes contain a variety of biosynthetic gene
clusters (BGCs) belonging to the major biosynthetic classes (Fig. 2). On average, a
Nocardia genome features 36 BGCs and a predicted overall chemical/metabolic diver-
sity of 35% NRPs, 18% PKs, 13% terpenoids, 12% hybrids, 2.2% bacteriocins, 2.2%
arylpolyenes, 2% butyrolactones, 1.1% RiPPs, and 14.5% others. Gratifyingly, the num-
ber of identified pathways did not correlate with the number of contigs per genome
(R2  0.28; see Fig. S32 at https://doi.org/10.5281/zenodo.3784407). Although this
warrants a certain degree of robustness to our data, actual BGC numbers might vary
slightly, as antiSMASH results were not reinspected for broken or merged clusters.
Interestingly, we could observe a correlation between the phylogenetic clade and BGC
abundance. Clades A, E, and F contain on average more BGCs than clades B and C.
However, even in strains with relatively low BGC numbers, at least 16 BGCs were
FIG 2 Nocardia phylogeny and BGC distribution. Maximum likelihood tree of 103 members of the genus Nocardia based on 63 concatenated housekeeping
genes identified with autoMLST (see Fig. S2 and Table S3 at https://doi.org/10.5281/zenodo.3784407). Ultrafast bootstrap values were calculated using 1,000
replicates. Numbers next to the bars (predicted BGCs by antiSMASH) represent genome sizes (in megabase pairs). Average numbers of BGCs per clade are
shown. X labels a distinct branch formed by a single Nocardia strain, Nocardia harenae NBRC 108248.
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detected. Similar to their sister genus Rhodococcus, the most prevalent BGCs in Nocar-
dia are NRPSs (18). A positive correlation was found between the number of biosyn-
thetic gene clusters in each strain predicted by antiSMASH and the respective genome
size (see Fig. S1 at https://doi.org/10.5281/zenodo.3784407). Overall, the established
biosynthetic capabilities of Nocardia strains are comparable to those of Streptomyces
and Amycolatopsis, based on recently reported diversity plots (18–20).
Genomic features of clinically relevant Nocardia strains. Mycobacterium and
Rhodococcus pathogenic strains generally have smaller genomes as well as fewer and
less diverse BGCs than the rest of the respective genera (21). The opportunistic nature
of nocardiosis, the high diversity of causative species, and the insufficient knowledge
on Nocardia virulence factors makes the distinction of pathogenic and nonpathogenic
strains difficult. Accordingly, we were not able to observe a correlation between the
genome size or BGC content and the different sources of isolation (see Fig. S30 at
https://doi.org/10.5281/zenodo.3784407). It is fair to assume that in principle, many
Nocardia strains can act as facultative pathogens. Nevertheless, some Nocardia species
are reported more often from nocardiosis patients than others, i.e., N. asteroides, N.
cyriacigeorgica, N. brasiliensis, N. abscessus, N. farcinica, N. nova, and N. otitidiscaviarum,
further referred to as group 1 pathogens (6, 22–24). Indeed, the genomes of these
pathogens are on average slightly smaller than the rest of the genus (7.4 Mbp versus
7.8 Mbp) and contain fewer BGCs (32.5 versus 36.5). A remarkable exception are the
different strains of N. brasiliensis with genomes of 9.4 (ATCC 700358), 9.2 (IFM 10847),
and 8.9 (NBRC 101014) Mbp in size and an outstanding chemical potential with 49, 56,
and 49 predicted BGCs, respectively. It is notable that N. farcinica IFM 10152, a clinically
prevalent group 1 pathogen, with 6.3 Mbp contains the smallest genome and the
lowest number of predicted BGCs (16 BGCs) of all Nocardia. Intriguingly, a majority of
these clusters are conserved in other Nocardia spp., sometimes throughout the genus
(see Table S22 at https://doi.org/10.5281/zenodo.3784407). It could be speculated that
the BGCs found in N. farcinica represent some version of a minimal secondary metabo-
lome required to support both a lifestyle as a soil-dwelling saprophyte and as a
successful opportunistic pathogen. A preliminary survey of putative Nocardia virulence
factors such as catalases and superoxide dismutases showed no significant trend
regarding number and identity of respective genes in group 1 strains versus the rest of
the genus (see Table S21 at https://doi.org/10.5281/zenodo.3784407). This could sug-
gest that strain-specific pathogenicity is mainly driven by other characteristics.
Metabolic diversity and gene cluster families in Nocardia. To assess the diversity
of BGCs in the genus in more detail, we performed a network analysis using the
BiG-SCAPE algorithm. BiG-SCAPE employs Pfam composition similarity to calculate BGC
distances that takes a weighted combination of the Jaccard index, adjacency index, and
domain sequence similarity score into account (14, 25). The generated sequence
similarity network with a default similarity score cutoff of c 0.5 (equals threshold of
50%) consisted of 2,836 BGCs as unique nodes and 22,455 edges (Fig. 3 and 4).
Altogether, 258 independent gene cluster families (GCFs) were formed with two or
more nodes and 750 singletons. Notably, several large superclusters are visible, which
are composed of subclusters with apparently different biosynthetic features (Fig. 4).
These superclusters could not be satisfyingly resolved using higher similarity cutoffs or
different alignment modes. Such problems have been reported from other comparative
genome analyses and attributed to fragmented genome assemblies and deficient
separation of individual BGCs by antiSMASH. (18). Indeed, manual inspection of the
Nocardia BGC similarity network revealed a number of distinct subclusters we consid-
ered additional GCFs (Fig. 4). Next, we wanted to assess whether the clinically most
relevant Nocardia species exhibit a characteristic secondary metabolism and con-
ducted a number of statistical analyses. Boxplots along with t test indicate that the
BGC class frequency distribution between group 1 and other Nocardia genomes is
insignificant (see Fig. S33 at https://doi.org/10.5281/zenodo.3784407). Moreover,
principal-component analysis (PCA) plots show that the GCF presence/absence infor-
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mation is insufficient for clustering the Nocardia genomes into separate groups based
on clinical annotations (group 1; see Fig. S34 at https://doi.org/10.5281/zenodo
.3784407). Overall, it appears that none of the BGCs are significantly more abundant or
even specific to prevalent Nocardia pathogens in comparison to the rest of the genus.
However, correlation can be observed between phylogenetic clades and BGC distribu-
tion within the sequence similarity network (Fig. 3). In particular, strains from clade E
feature a number of clusters that are not found in bacteria from other clades, including
pathways for terpenoid, NRPS, and PKS biosynthesis. For example, a gene cluster with
high similarity to hopene biosynthesis is found in all Nocardia of clade E and otherwise
only in Nocardia transvalensis NBRC 15921. Hopanoids (Fig. 1) are pentacyclic triterpe-
noid components of membranes from diverse prokaryotes (26). They have stabilizing
functions similar to sterols in eukaryotes and might be of use to members of clade E in
specific environments. In contrast, BGCs of Nocardia spp. attributed to clade F do not
form a single characteristic GCF with representatives from more than seven strains.
A number of GCFs comprise clusters, which are highly abundant in the investigated
Nocardia genomes (Fig. 4). This includes several GCFs that represent pathways with
mono-modular type I PKS-like ketosynthases, i.e., GCF 1, 11, and 14, potentially involved
in the modification of fatty acid precursors. For example, GCF 1 represents a highly
conserved cluster found throughout the genus, which likely directs the synthesis of
mycolic acids. Mycolic acids (Fig. 1) are characteristic and essential cell wall components
of mycobacteria and related genera, e.g., Corynebacterium, Rhodococcus, Gordonia, and
Nocardia (27). Depending on the producing organism, these molecules differ in chain
length and degree of unsaturation. Nocardia mycolic acids usually consist of a C32-40
-hydroxy chain and a C12-18 -alkyl side chain. A typical cluster of GCF 1 encodes a
FIG 3 BiG-SCAPE sequence similarity network (SSN) and nocobactin-like subfamilies visualized in Cytoscape. (A) SSN (c 0.5) of Nocardia spp. Each node
represents one BGC identified by antiSMASH 4.0. Colors represent phylogenetic clades A to F and X. Clade-specific GCFs are highlighted. (B) SSN (c 0.7) of
nocobactin-like BGCs. Representative pathways of different subfamilies (I to IX). Two singletons (X and XI) are shown. Abbreviations: TE, thioesterase; KS,
ketosynthase; PKS, polyketide synthase; NRPS, nonribosomal peptide synthetase; NMO, N-monooxygenase; NAT, N-acetyltransferase; NFT, N-formyltransferase;
SHMT, serine hydroxymethyltransferase.
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homolog of Pks13, the essential condensing enzyme to form mycolic acid from two
fatty acyl coenzyme A (acyl-CoA) precursors (28). It contains additional genes that are
assigned to the biosynthesis and transfer of arabinose and galactose. Together, these
enzymes presumably participate in the assembly of the Nocardia mycolyl-arabino-
galactan-peptidoglycan complex. Nocardiolactone (Fig. 1) is a fatty acid derivative with
similarity to lipstatin that has been isolated from different Nocardia strains (29).
Recently, Robinson and coworkers reported on the identification of the nocardiolac-
tone gene cluster featuring a -lactone synthetase (30). -Lactone-containing natural
products are potent inhibitors of diverse hydrolytic enzymes, and their biosynthesis has
FIG 4 BiG-SCAPE cluster type sequence similarity network of all BGCs from Nocardia strains found with antiSMASH
4.0. Colors show cluster types from Nocardia BGCs. Colorless nodes are hybrid BGCs found in Nocardia. Bold node
borders refer to group 1 pathogens.
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drawn a lot of attention (31–33). The lower subcluster of GCF 11 contains 36 homol-
ogous nocardiolactone BGCs of which six have been initially assigned by antiSMASH as
putative lipstatin-type pathways (Fig. 4).
The BGCs that form GCF 2 are found in all Nocardia genomes and encode enzymes
for the synthesis of ectoine (Fig. 1), a compatible solute which stabilizes biopolymers
(DNA, proteins, etc.) under extreme conditions (34). The capability to produce ectoine
or 5-hydroxyectoine is not uncommon to actinobacterial genera such as Streptomyces
and Mycobacterium (35, 36). The strict conservation of this pathway in Nocardia seems
to reflect a general requirement of all members of the genus to be able to function
under osmotic stress. It was recently shown that the ectoine BGC is similarly conserved
in the sister genus Rhodococcus (18).
Nocardia are known to produce colorful pigments ranging from yellow to red, but
a systematic analysis of the carotenoid content in this genus has not been conducted
(7). GCF 3 summarizes pathways that are likely responsible for the formation of a
carotenoid of unknown structure. The BGC is highly conserved in all Nocardia genomes.
It encodes polyprenyl synthase (CrtE), phytoene synthase (CrtB), and phytoene desatu-
rase (CrtI) homologs for the production of lycopene. An obvious candidate for a cyclase
is not found in the cluster. However, a putative lycopene cyclase present in all Nocardia
species is the main feature of the conserved terpene GCF 10. Together, both BGCs could
direct the concerted biosynthesis of mono- or bicyclic carotenes. Further modifications
may involve the attachment of a glycosyl group similar to sioxanthin (37). Such
monocyclic carotenoid glycosides and their esters (Fig. 1) have been isolated from
Nocardia kirovani and different Rhodococcus species (38, 39). Arylpolyenes are another
common class of pigments and generated by an unusual type II PKS system. These
molecules are mostly known from Gram-negative gammaproteobacteria and bacte-
roides (25). A pathway with signature motifs for the synthesis of aryl polyenes is
widespread in Nocardia (82 of 101 genomes) and clustered in GCF 8.
The gene clusters organized in GCF 4 are also found in all Nocardia species. Here, a
single NRPS with four modules is colocated with a putative N-acyltransferase and two
transporters. The produced peptide likely consists of an N-terminal serine and three
additional amino acids. The three residues cannot be predicted with certainty from the
respective incorporating A domains but presumably feature aliphatic or aromatic side
chains (see Table S4 at https://doi.org/10.5281/zenodo.3784407). Two other conserved
NRPS pathways could be identified. One of them (GCF 5) consists of a trimodular NRPS
gene with epimerization (E) domains encoded in the first module and in the terminal
module. A peptide sequence could not be predicted on the basis of the A domains. This
BGC is present in 75 out of 101 Nocardia genomes. Similarly conserved is a large NRPS
assembly line of different size represented by GCF 6. The enzyme complex may contain
7 to 13 modules, but the gene cluster environment is invariant and always encodes a
putative nitropropane dioxygenase, a metallopeptidase, an esterase, an epimerase, and
an enoyl-CoA dehydratase.
Linocin M18 has been described as a secreted bacteriolysin (formerly type III
bacteriocin) from Brevibacterium linens M18 (40). Similar proteins were found in various
other bacteria, including Mycobacterium tuberculosis and Burkholderia cepacia complex.
They could be associated with pathogen-host cell attachment and immunogenicity (41,
42). Moreover, linocins have been shown to form multimeric microcompartments (43).
A respective orthologous gene is encoded in all Nocardia genomes and summarized in
GCF 9.
The gene cluster family of nocobactins. Another highly abundant BGC family (GCF
7) is found in 92 of 101 Nocardia genomes and encodes a conserved hybrid NRPS/PKS
pathway annotated by antiSMASH as putative nocobactin NA BGC (50% homology;
Fig. 3A). Nocobactin NA (Fig. 1) was first reported in 1974 as a UV-active siderophore
from cultures of N. asteroides by Ratledge and Snow (44). Nocobactins were subse-
quently found in other Nocardia spp., but not in Rhodococcus (45). A number of
derivatives have been isolated since, including the amamistatins, nocardimicins,
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brasilibactin, formobactin, and terpenibactins (46–50), which all share a
hydroxyphenyloxazoline/-oxazole moiety, a N-acetylated or N-formylated N-hydroxy-
lysine that is linked via an ester moiety to a long-chain -methyl, -hydroxy fatty acid,
and a C-terminal N-hydroxy -amino -caprolactam ring. The biosynthetic pathway for
nocobactin NA reported from N. farcinica IFM 10152 involves a nonlinear assembly line
consisting of three NRPS modules and one PKS module (Fig. 5) (51). NbtF (T-cyclization
domain [Cy]-A-T) is proposed to catalyze the condensation and heterocyclization of
salicylic acid and threonine with the help of the stand-alone A-domain NbtT. NbtD
(C-A-T-C-T) activates and adds lysine, or a derivative, to the growing chain. NbtH and
NbtG, either before or after incorporation of the lysine moiety, likely direct N-acylation
and N-hydroxylation, respectively. NbtB (KS) and NbtC (AT-ketoreductase [KR]
domain-T) are proposed to be responsible for the activation of a fatty acid which is
extended by Claisen-type condensation with methylmalonyl-CoA and subsequently
reduced at the -position. The incorporation of the fatty acyl moiety by ester linkage
is probably mediated by NbtD before NbtE (C-A-T-E) attaches another lysine. Epimeriza-
tion of this amino acid to the D isomer is followed by N-hydroxylation and formation of
the -caprolactam. Notably, the nocobactin pathway is split in two gene clusters, which
are located 180 kb apart on the N. farcinica IFM 10152 chromosome. Cluster I contains
the majority of the biosynthetic genes, whereas cluster II codes for NbtT and a putative
salicylate synthase, NbtS. This splitting is reflected in the BiG-SCAPE similarity network
by GCF 13 that is annotated by antiSMASH as mycobactin-like with 30% similarity. In
fact, this GCF contains a small pathway of three conserved genes with high homology
to nbtT, nbtS, and nbtF. It appears that nocobactin cluster II (which is not deposited in
the MIBiG database) is recognized bioinformatically only if the NRPS module NbtF is
FIG 5 Model for nocobactin NA biosynthesis. NRPS/PKS domains: adenylation (A), thiolation (T), heterocyclization (Cy), condensation (C),
epimerization (E), ketosynthase (KS), acyltransferase (AT), ketoreductase (KR), aryl carrier protein (TAr), methylmalonyl CoA (mm-CoA).
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encoded. Indeed, all strains containing such a cluster II variant lack an nbtF homolog in
their respective nocobactin cluster I. This pathway organization is shared by almost 45%
of Nocardia spp. The widespread occurrence of the nocobactin NA-like pathway in
Nocardia genomes indicates a constitutive role for this siderophore in the biology of the
genus. Structurally and biosynthetically, the nocobactins are closely related to the
mycobactins which have similar prominence in mycobacteria (52). Both compound
classes differ in the chain length of their acyl substituents. Mycobactins feature a
long-chain fatty acid attached to the N-hydroxylysine moiety instead of the formyl/
acetyl group in nocobactin-like molecules and a central 3-hydroxybutyrate group. They
are the quintessential siderophores for the genus Mycobacterium and are produced by
all species except M. paratuberculosis. These molecules exist typically as membrane-
bound iron scavengers but can also be produced in a more polar form as extracellular
carboxymycobactins (53). Mycobactins of both variants are important for the lifestyle of
pathogenic mycobacteria and have been shown to play a fundamental role in the
survival and growth of M. tuberculosis in human macrophages (54, 55). It is tempting to
speculate that nocobactins may have a similar function as virulence factors in the
progression of nocardiosis. The first evidence for this theory was obtained by Hoshino
et al. studying ΔnbtE deficient mutants in infection assays with the macrophage-like cell
line J774A.1 (51).
To assess the metabolic diversity of nocobactins in the genus Nocardia, we analyzed
the composition of the BGC family generated by BiG-SCAPE in more detail. Notably, the
nocobactin GCF obtained with a threshold of 50% shows two prominent subclusters
(Fig. 3A). Both subclusters are characterized on a genetic level by the exclusive presence
of a gene for an N-acetyltransferase (NbtH homolog) or an N-formyltransferase. This
finding suggests that the subdivision of the nocobactin GCF reflects the production of
structurally different derivatives with either an acetyl or formyl group attached to the
N-hydroxylysine residue. From the reported nocobactin-like siderophores, nocobactin
NA and nocardimicins A to F feature an acetyl moiety, whereas nocardimicins G to I,
formobactin, brasilibactin, amamistatins, and terpenibactins feature a formyl moiety. A
candidate enzyme for this reaction, TerH, has been identified in the terpenibactin
pathway (50). Further refinement of the BiG-SCAPE similarity network with a threshold
of 70% resulted in the segmentation of the nocobactin cluster I GCF to nine indepen-
dent families of more than two BGCs (further referred to as nocobactin-like BGC
subfamilies) and nine singletons (Fig. 3B). Interestingly, the composition of these new
subfamilies correlates to some degree with the phylogenetic clades observed by
autoMLST analysis. Subfamilies II, V, VIII, and IX consist solely of pathways from clades
E, B, C, and F, respectively. Subfamilies I and VII are dominated by clades D and F and
clades A and B, respectively. Again, the absence or presence of NbtH/TerH homologs is
a major discriminating factor that determines these subfamilies. Subfamilies I and III
carry a gene that encodes an NbtH, and subfamilies II, IV, VI, and VII to IX carry a gene
that encodes a TerH homolog. Only subfamily V comprises pathways that contain either
an nbtH or terH gene. Additionally, splitting of subfamilies is based on the clustering of
the nbtF homolog. Subfamilies II, III, VI, VII, VIII, and IX exhibit a putative nbtF gene in
cluster I, whereas in subfamilies I, IV, and V, nbtF is colocated with cluster II. Further
characteristic family features are additional and/or alternative NRPS modules in sub-
families II, VI, VIII, and IX. Here, the nocobactin-like pathways have a gene that encodes
a discrete C-T didomain protein, probably a functional substitute to the missing
terminal C-T domains of the NbtD homolog, and another NRPS enzyme with a C-A-T-
E-C domain structure. The specificity of the corresponding A domain could not be
predicted bioinformatically. It is worth mentioning that the previously reported
nocobactin-type molecules exhibit diverse stereochemical configurations. Nocobactin
NA features a central acylated N-hydroxy L-lysine and a terminal N-hydroxy D-lysine
1,6-lactam. In contrast, amamistatin A incorporates D- and L-lysine and brasilibactin A
incorporates D- and D-lysine derivatives at these positions, respectively (51, 56, 57).
Possibly, the production of different stereoisomers might rely on the presence of
additional E-domain-containing NRPS enzymes as found in subfamilies II, VI, VIII, and IX.
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Moreover, in subfamilies VI and VIII, the PKS enzymes with NbtC homology are
extended by a C-methyltransferase domain to an AT-KR-T-cMT module with predicted
AT domain specificity to methylmalonyl-CoA (mmal-CoA). Notably, formobactin A and
the amamistatins contain a rare -dimethylated fatty acid which could derive from such
a biosynthetic setup. It is also worth mentioning that the colocalization of a gene for
a putative SagB-type dehydrogenase is characteristic for the clusters subsumed in
subfamilies I, III, V, and VII. SagB is involved in the biosynthesis of streptolysin S toxin
by catalyzing the oxidation of oxazoline and thiazoline heterocycles to form oxazole
and thiazole ring structures (58). Interestingly, both heterocyclic variants exist in
nocobactin-type siderophores, with oxazole moieties in nocobactin NA, formobactin,
the amamistatins and nocardimicins A to F, and oxazolines in brasilibactin A, no-
cardimicins G to I, and the terpenibactins. The established subfamilies can also be
distinguished based on the association of the pathways with transporter genes. In
subfamilies II, IV, VI, VIII, and IX, such functionalities are encoded in the same operon as
the biosynthetic genes. In subfamilies I, III, V, and VII, transporters are encoded
immediately adjacent to the clusters. Nine gene clusters were not clustered with the
other subfamilies. One of these pathways (X), found in Nocardia fusca NBRC 14340,
contains homologs to all genes of the nocobactin NA gene cluster. Additionally, it
features a second copy of nbtF, a terH homolog, a gene for a discrete A domain and a
putative serine hydroxymethyltransferase gene. Another singleton cluster (XI) is en-
coded in Nocardia vermiculata NBRC 100427 exhibiting two copies of an nbtABC-like
operon but lacking nbtD, nbtG, and nbtH/terH-like genes. The missing homologs are
located in an independent cluster together with genes for a second NRPS C-A-T-E-C
module and several transporters.
Nocobactin-like molecules produced by different Nocardia strains. Clearly, the
different families obtained from the BiG-SCAPE similarity network are composed of
pathways with characteristic biosynthetic functionalities. We next wanted to inquire
how these distinct cluster organizations correspond to structural diversity in the
produced nocobactin-type siderophores. Therefore, we examined the intracellular and
membrane-associated culture fractions from a selection of Nocardia strains represen-
tative of the identified nocobactin-like BGC subfamilies (see Table S19 at https://doi
.org/10.5281/zenodo.3784407). The culture extracts were subjected to positive ion
mode liquid chromatography-mass spectrometry (LC-MS) analysis. To stabilize mole-
cules with metal-chelating properties and facilitate their identification, we supple-
mented the samples with Ga2(SO4)3 under reducing conditions. This treatment resulted
in the almost complete equipment of metal-free siderophores with Ga(III) and largely
replaced Fe(III) in already loaded compounds. The generated gallium complexes could
be detected by mass spectrometry via their distinct isotopic pattern. The tandem mass
spectrometry (MS/MS) spectra obtained from data-dependent acquisition experiments
were used to construct a molecular network with the help of the GNPS (Global Natural
Product Social Molecular Networking) platform (59). For an internal reference, we
included pure samples of the recently discovered terpenibactins in our analysis (see
Table S5 at https://doi.org/10.5281/zenodo.3784407) (50). The resulting network of
ionizable metabolites from 12 Nocardia strains together with the terpenibactins rep-
resented 3,567 nodes and 4,177 edges (Fig. 6). At a cosine value of 0.6, it forms 108
clusters of two or more nodes and shows 2,470 singletons. The observed clusters likely
represent molecular families of compounds with similar chemical structures. The
terpenibactins clustered with one molecular family containing 21 putative metabolites
of seven analyzed Nocardia strains. A closer inspection showed that this association is
based on the consistent fragmentation of the terpenibactins along the ester linkage
between the modified lysine residue and the -hydroxy fatty acid moiety. This pro-
duces characteristic fragment ions of m/z 460.0621 (major), m/z 414.0552 (major), and
m/z 442.0477 (minor) for terpenibactin A (see Fig. S4 at https://doi.org/10.5281/zenodo
.3784407). A similar pattern can be observed for terpenibactin B and terpenibactin C
with deviating fragment ions containing the variable fatty acyl moiety (see Fig. S3 at
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https://doi.org/10.5281/zenodo.3784407). Additional prominent fragments ofm/z 145.1
and m/z 171.08 are found in most MS/MS spectra and likely represent the caprolactam
moiety. Using these results as fingerprints, we interpreted the other spectra clustered
with the terpenibactins. In consideration of the biosynthetic information deduced from
the gene clusters and the already known chemical diversity, we postulated possible
structures for each of the produced nocobactin derivatives (Fig. 7; see Fig. S5 to S21 and
Tables S6 to S15 at https://doi.org/10.5281/zenodo.3784407). The first thing to note is
that representatives of all investigated subfamilies seem to synthesize molecules with
only minor structural differences to nocobactin NA. The predicted compounds all
comprise a phenoxazoline/-oxazole, an acylated N-hydroxylysine, a hydroxy fatty acid,
and a caprolactam moiety. The integrity of this core structure was independent of the
composition of the respective BGCs, e.g., the presence of additional NRPS genes
(subfamilies II, VI, VIII, and IX), duplication of the PKS genes (subfamily XI) or absence
of the nbtF homolog in cluster I (subfamilies I, IV, V, and X). However, the MS/MS
characteristics of the different identified nocobactin-type molecules are in accordance
with the presence of nbtH (N-acetyltransferase) or terH (N-formyltransferase) homologs
and PKS C-methyltransferase domains in their respective gene clusters. This supports
our bioinformatic predictions that generally pathways from subfamilies I, III, and V
produce acetylated nocobactin derivatives and pathways from subfamilies II, IV, and VI
to IX produce formylated nocobactin derivatives. Strikingly, colocation of a sagB-like
dehydrogenase gene with the nocobactin biosynthetic pathway in subfamilies I, III, and
VII led to the almost exclusive production of molecules with a predicted phenoxazole
moiety. The absence of such a gene in subfamilies II, IV, VI, and VIII to XI, on the other
hand, correlated with the accumulation of phenoxazoline-containing compounds. This
strongly indicates that the SagB-type dehydrogenase is involved in the oxidation of the
oxazoline ring in the biosynthesis of this class of siderophores. Our genomics-to-
metabolomics analysis of Nocardia alba NBRC 108234 (subfamily I) suggests that this
FIG 6 Molecular MS/MS network of culture extracts from selected Nocardia strains. The color of the node indicates the source of the
ions. Bold node borders indicate putative carboxynocobactins. Molecular families containing putative siderophores a (nocobactin-
type) and b (mycobactin-type) are highlighted by gray framed boxes. The structure of the identified mycobactin-type compound from
N. araoensis NBRC 100135 with an exact mass of 773.4569 Da and m/z 840.3669 [M-2HGa] is shown in complex with gallium.
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strain synthesizes nocobactin-type siderophores with a nonmethylated oxazole moiety
and a N-acetyl group (Fig. 7). This closely resembles the structures of the already known
nocardimicins A to F. Indeed, exact mass and MS/MS spectra of ions with m/z 796.3043
[M-2HGa], m/z 824.3356 [M-2HGa], and m/z 852.3669 [M-2HGa] perfectly
match those of nocardimicins A, B, and D, respectively (see Fig. S18 to S20 at https://
doi.org/10.5281/zenodo.3784407). In addition, we would postulate that Nocardia el-
egans NBRC 108235 (subfamily II) and Nocardia jejuensis NBRC 103114 (subfamily IX)
produce N-formylated nonmethylated oxazoline-containing molecules with MS char-
acteristics identical to those of nocardimicin G and nocardimicin H (see Fig. S15 and S16
at https://doi.org/10.5281/zenodo.3784407). Similar molecules are produced by N.
cyriacigeorgica GUH-2, the representative of subfamily VI. This subfamily also comprises
the three BGCs found in N. brasiliensis strains ATCC 700358, IFM 10847, and NBRC
14402, respectively. It is noteworthy that a nocardimicin analog, brasilibactin A, has
previously been isolated from this species (48). Closer inspection of the N. cyriacigeor-
gica GUH-2 extract revealed an ion with m/z 868.3966 [M-2HGa] matching the
predicted MS properties of brasilibactin A (see Fig. S21 at https://doi.org/10.5281/
zenodo.3784407). Moreover, gene cluster and MS analysis of Nocardia gamkensis NBRC
FIG 7 Production of nocobactin-type siderophores by selected Nocardia strains from subfamilies I to XI. Representative compounds are depicted.
Structures shown in I, II, and VI to XI were predicted from HRMS and MS/MS experiments. An asterisk indicates that the structures shown in III
and IV have been adopted from literature (50, 51).
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108242 (subfamily VII) conform to the synthesis of nocobactin derivatives comprising a
methyloxazole, an N-formyl group, and a central gem-dimethylated hydroxy fatty acid
moiety. Such a core skeleton is known from formobactin and the amamistatins. Based
on high-resolution MS (HRMS) and MS/MS spectra, the detected compound with m/z
810.3199 [M-2HGa] does indeed correlate with formobactin (see Fig. S12 at https://
doi.org/10.5281/zenodo.3784407). Overall, we have identified candidate gene clusters
for the biosynthesis of formobactin, the nocardimicins, and brasilibactin and provided
the first evidence for their function. The pathways for these molecules have not been
reported so far. Moreover, the production of these and the other known nocobactin-
like siderophores, nocobactin NA and terpenibactin, corresponds to the assignment of
their gene clusters to different subfamilies. Notably, the biosynthetic pathways clus-
tered in subfamily VIII appear to produce variants of this structural class that have not
been described before. The representative investigated, Nocardia rhamnosiphila NBRC
108938, accumulates a molecule likely containing a nonmethylated oxazoline, an
N-formyl group, and a gem-dimethylated hydroxy fatty acid moiety. We are currently
pursuing isolation and characterization of this new compound in detail. Another
interesting finding are two metabolites from N. gamkensis NBRC 108242 which exhibit
the characteristic MS fragmentation pattern of nocobactins but have a mass indicating
the presence of a carboxyl group. The detection of MS fragments with m/z 458.0477,
m/z 412.0432, m/z 171.0688, and m/z 145.0981 for parent ion m/z 840.2982 [M-
2HGa] and fragments m/z 458.0450, m/z 412.0419, m/z 171.0480, and m/z 145.0894
for parent ion m/z 812.2634 [M-2HGa] implies intact phenyl methyloxazole,
N-formylated N-hydroxylysine, and -caprolactam moieties. This suggests that it is the
central hydroxy fatty acyl unit, which is modified by an additional carboxylic acid group.
Such structural variations are known from carboxymycobactins, the extracellular ver-
sion of mycobactins, which contain ,-dicarboxylic acids (53). Analogously, the two
molecules detected may represent “carboxynocobactins,” the first examples of similarly
oxidized nocobactin-like siderophores. We are currently further exploring this hypoth-
esis.
Next, we wanted to validate our MS- and genomic data-based structure prediction
strategy. We were particularly interested to examine molecular variations that are
invisible to our MS/MS analysis design and are thus mainly deduced from gene cluster
content. One such example is the location of an additional methylene unit (14 Da) in
fragment ions representing the western part of the molecule, e.g., in m/z 838.3512
[M-2HGa] from N. alba NBRC 108234 (see Fig. S23 at https://doi.org/10.5281/zenodo
.3784407). In theory, this could derive either from the presence of a methyloxazoline or
an N-acetyl group in the respective compounds. Therefore, we fed L-[13C1]serine to
cultures of N. alba NBRC 108234 and analyzed the culture extracts by LC-MS. Detection
of parent ion m/z 839.5489 [M-2HGa1] and fragments m/z 413.2523 and m/z
441.2829 indicate the incorporation of L-serine into the oxazoline ring and, hence, the
presence of an N-acetyl group (see Fig. S23 and S24 at https://doi.org/10.5281/zenodo
.3784407). For mycobactin biosynthesis, it has been proposed that the oxazoline ring
derives from demethylation of a methyloxazoline moiety (60). However, our data
suggest that for nocobactin-type siderophores in Nocardia spp., the selected methyl-
ation of the oxazoline ring instead depends on the specificity of the respective A
domain in the NbtF homolog toward threonine or serine.
Identification of a mycobactin-type molecule produced by N. araoensis NBRC
100135. We were not able to identify nocobactin-type molecules from Nocardia
araoensis NBRC 100135 and N. takedensis NBRC 100417, although both have the
biosynthetic capacity in the form of pathways belonging to subfamilies III and VII,
respectively (see Table S18 at https://doi.org/10.5281/zenodo.3784407). This finding
made us curious, and we reexamined the culture extracts of these strains to identify
putative alternative siderophores. More precisely, we searched the respective MS
spectra for molecular ions with a mass shift and isotope pattern that indicated the
scavenging of Ga3. Indeed, we found the ions of putative siderophores in the same
mass range as that for the nocobactins, e.g., m/z 824.3353 [M-2HGa], m/z 840.3669
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[M-2HGa], and m/z 854.3817 [M-2HGa]. Intriguingly, MS/MS experiments pro-
duced signal spectra that would instead correlate with mycobactin-type molecules,
wherein the long fatty acid moiety is N-acylated on the N-hydroxylysine instead of
being incorporated by NbtB and NbtC in the polyketide extension comprising the ester
linkage. To explore this possibility, we isolated a compound with the mass of
773.4569 Da from culture extracts of N. araoensis NBRC 100135. Following overnight
incubation of this unknown putative mycobactin-like siderophore with Ga2(SO4)3 dis-
solved in methanol, we removed the residual solvent and resuspended it in CDCl3 for
a suite of one-dimensional (1D) and 2D nuclear magnetic resonance (NMR) spectro-
scopic analyses. Structural assignment of the gallium-bound siderophore (Fig. 6; see
Table S17 and Fig. S25 to S29 at https://doi.org/10.5281/zenodo.3784407) allowed us to
identify key spin systems by total correlation spectroscopy (TOCSY): an ortho-
disubstituted phenol, a serine-derived oxazoline, a linear saturated fatty acid, two
N-hydroxylysines, and most notably, a -hydroxybutyrate moiety. The presence of the
relatively simple -hydroxybutyrate spin system instead of the much more complex
-hydroxy fatty acid observed in the nocobactins further validated the prediction that
this molecule is indeed a mycobactin-like siderophore. It was determined that the fatty
acid was attached to the linear N-hydroxylysine side chain via key 1H-13C heteronuclear
multiple bond correlation (HMBC) cross peaks from the same amide carbonyl carbon to
both the amino acid -CH2 and the fatty acid -CH2, further supporting the MS/MS
fragmentation data regarding the location of this moiety. A direct NMR comparison of
this novel metabolite to the most structurally similar molecules (mycobactin S or
BE-32030 B from another Nocardia species [61]) was not performed due to the presence
of a chelating Ga3 ion within our analyses, while previous isolates contained the
metal-free forms. One beneficial outcome of the addition of gallium is that it minimized
rotomeric forms of this peptide and easily identified groups adjacent to metal-chelating
moieties (the -CH2 groups of both N-hydroxylysines and the -CH2 of the fatty acid)
due to the strong diastereotopic shifts from chiral coordination to the metal ion. The
nocobactin-type BGCs from N. araoensis NBRC 100135 and N. takedensis NBRC 100417
are genuine representatives of subfamilies III and VII, respectively. They are almost
identical to the pathways of N. farcinica IFM 10152 and N. gamkensis NBRC 108242,
respectively, the other investigated members of those clades. On the basis of these
gene clusters, it is difficult to explain why they would support the production of
mycobactins instead of nocobactins. We would speculate that for the biosynthesis of
mycobactins in Nocardia spp., trans-encoded enzymes are recruited from other meta-
bolic pathways, e.g., a long-chain fatty acid N-acyltransferase.
Conclusion. Our comparative genomic survey of the actinobacterial genus Nocardia
revealed a highly diverse biosynthetic capacity for natural products which rivals better
investigated genera such as Streptomyces and Amycolatopsis. Most of the GCFs identi-
fied by BGC similarity networks could not be correlated with known compounds,
making Nocardia a promising source for the discovery of new drug leads. Other GCFs
are widespread in or even constitutive for this genus, raising interesting questions
about their role in bacterial physiology, ecology, and pathogenesis. By using the highly
conserved biosynthetic pathway for nocobactin-type siderophores as a proxy, we
sought to address the longstanding question of the relationship of BGC homology and
chemical diversity. We could show that at least for this case, the BiG-SCAPE gene cluster
subfamilies generated by a similarity cutoff of 0.7 encoded structurally distinct noco-
bactin derivatives. These congeners differed in oxidation state and the selected pres-
ence of various methyl groups. By using this approach, we were able to assign for the
first time BGC candidates to the nocardimicins, formobactin, and brasilibactin. More-
over, we identified the Nocardia strains of subfamily VIII that likely produce so far
undescribed nocobactin variants. Our study shows the successful linkage of compara-
tive genomics data to chemical analytics data for refined chemical structure prediction.
It exemplifies how multi-omics data can be implemented into drug discovery and aid
dereplication efforts. With public repositories such as MassIVE and MetaboLights for
Nocardia Genomics to Metabolomics
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MS/MS data and additional community tools, which provide links to genomic data (e.g.,
http://pairedomicsdata.bioinformatics.nl), this approach will be even more powerful in
the future. Our results will thus facilitate future genome mining approaches and open
the door for the targeted exploitation of the genus Nocardia for natural product
discovery.
MATERIALS AND METHODS
Strains and growth conditions. Chemicals, microorganisms, and molecular biological agents were
purchased from standard commercial sources. Nocardia araoensis NBRC 100135, Nocardia cyriacigeorgica
GUH-2, Nocardia takedensis NBRC 100417, Nocardia sp. strain Root136, Nocardia terpenica IFM 0406, Nocardia
jejuensis NBRC 103114, Nocardia fusca NBRC 14340, Nocardia rhamnosiphila NBRC 108938, Nocardia vermicu-
lata NBRC 100427, Nocardia gamkensis NBRC 108242, Nocardia elegans NBRC 108235, Nocardia seriolae DSM
44129, and Nocardia alba NBRC 108234 were obtained from the German Collection of Microorganisms and
Cell Cultures (DSMZ). Strains were grown and maintained either on tryptic soy broth (TSB) (pancreatic digest
of casein [17 g/liter], papaic digest of soybean [3 g/liter], sodium chloride [5 g/liter], dipotassium phosphate
[2.5 g/liter], dextrose [2.5 g/liter]) purchased from Becton Dickinson or brain heart infusion (BHI), purchased
from Sigma-Aldrich.
Nocardia genomic data. All Nocardia genome sequences used in this study were downloaded from
the National Center for Biotechnology Information (NCBI) database or the Department of Energy (DOE)
Joint Genome Institute – Integrated Microbial Genomes & Microbiomes (JGI IMG) database (62, 63).
Genomes that consisted of more than 615 contigs were discarded from analysis. The completeness of the
genomes were assessed using checkM (see Table S20 at https://doi.org/10.5281/zenodo.3784407) (64).
Phylogenetic analysis (autoMLST). A multilocus sequence analysis (MLSA) (65) was performed with
autoMLST using the web-based application at http://automlst.ziemertlab.com/analyze# with the “denovo
mode” and default settings (15). The resulting phylogenetic tree was visualized and modified in
Geneious.
In silico assessment of biosynthetic potential of Nocardia strains. In silico analysis was performed
with BLAST, antiSMASH 3.0 and 4.0 versions, and Geneious 9.1.8. BLASTP searches were performed using
the NCBI Protein BLAST program against the nonredundant protein sequence database (66).
BiG-SCAPE sequence similarity network. All files were processed using antiSMASH 4.0 including
the ClusterFinder border prediction algorithm (13, 25). The ClusterFinder border prediction algorithm
was used to automatically trim BGCs where gene cluster borders were possible to predict. To the
resulting 3,614 putative BGCs, 1,817 more were added from the MIBiG database as reference data (release
1.4, August 2018; see Fig. S31 at https://doi.org/10.5281/zenodo.3784407) (67). The final BGC set was
analyzed using BiG-SCAPE version 201804 implemented in Python 2.7.13 (14). The “hybrids” mode, which
allows BGCs with mixed annotations to be analyzed together, was enabled, and several cutoffs from 0.05
to 0.95 were tested. The program was run in both global and glocal alignment modes (see supplemental
material at https://doi.org/10.5281/zenodo.3784407). Obtained sequence similarity matrices were then
visualized using Cytoscape 3.6.1 (68).
Production conditions. Production of nocobactin- and mycobactin-like siderophores was achieved
by using Nocardia mycelium from petri dishes (80 mm by 2 mm) containing BHI agar for preculture
inoculation. Nocardia strains were cultured at 30°C and 200 rpm for at least 1 week. Five milliliters of
preculture was then used to inoculate a main culture and shaken at 30°C at 200 rpm for at least 20 days.
As production medium, a minimal medium (glycerol [20 ml/liter], L-asparagine [5 g/liter], KH2PO4 [5
g/liter or 50 g/liter] [pH 7.5]) was used as described previously (69). Chelex 100 sodium form, purchased
from Sigma-Aldrich, was added, and the medium was filtered through Whatman no. 541 filter papers to
remove Chelex. After autoclaving, media were supplemented with Zn2 (0.5 g/ml), Mn2 (0.1 g/ml),
Mg2 (0.04 mg/ml), and Fe2 (0.05 g/ml) or Fe2 (2 g/ml) for iron-deficient (main culture) or iron-
sufficient (preculture) growth, respectively. All Nocardia strains were cultured in 300-ml precleaned
Erlenmeyer flasks with 50 ml medium each at 30°C at 200 rpm. All glassware was precleaned by 2%
(wt/vol) alcoholic KOH/8 N HNO3 treatments according to Ratledge and Winder (70),
Extraction of mycobactin and nocobactin-like siderophores. After at least 2 weeks of inoculation,
mycelia were separated from the culture supernatant by centrifugation. Twenty-five milliliters of LC-MS
grade methanol was added to the cell pellet. After sonication and centrifugation, the organic phase was
isolated and evaporated under reduced pressure. The resulting crude extracts were dissolved in
methanol (MeOH). To obtain siderophores bound to gallium, a solution of gallium sulfate (20 mg in 30 ml
MeOH) was prepared. Ten milliliters was added to crude extracts and evaporated under reduced
pressure.
Isolation and purification of a mycobactin-like siderophore by HPLC. For the isolation of a
mycobactin-like siderophore from Nocardia araoensis NBRC 100135, an Agilent Technologies ProStar 410
Auto Sampler equipped with a Phenomenex Luna 5-m C18(2) 100-Å high-performance liquid chroma-
tography (HPLC) column (100 by 21.2 mm) was used with an Agilent Technologies 440-LC fraction
collector and a flow rate of 10 ml/min with water plus 0.02% formic acid as solution A and methanol with
0.02% formic acid as solution B (see Table S1 at https://doi.org/10.5281/zenodo.3784407). Fractions
generated were subjected to an Agilent Technologies 1100 HPLC system equipped with a Phenomenex
Luna 5-m C8(2) column (250 by 10 mm; 100 Å) at a flow rate of 3.5 ml/min (see Table S2 at https://doi
.org/10.5281/zenodo.3784407). The mycobactin-like siderophore with the mass of 840.367 [M-2HGa]
from N. araoensis NBRC 100135 eluted after 15.6 min. The peak was collected and dried to yield an
orange-to-red oil.
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Isolation of gDNA. To isolate genomic DNA (gDNA), Nocardia precultures from either BHI or TSB agar
plates were used to inoculate 50 ml of liquid TSB or BHI medium and cultivated for at least 2 weeks at
30°C and 200 rpm. Cells were harvested, and genomic DNA was isolated from Nocardia with standard
protocols for Streptomyces by phenol-chloroform extraction. Protocols were followed as described in
reference 71 with additional treatment of 40 mg proteinase K and subsequent incubation at 60°C for at
least 30 min, but no longer than 1 h, after the addition of sodium dodecyl sulfate (SDS).
16S rRNA gene analysis. To rule out contamination of Nocardia araoensis NBRC 100135 production
cultures, gDNA was isolated from respective precultures. The 16S rRNA gene was amplified by PCR with
the 27F and 1492R universal eubacterial 16S rRNA gene primer set and high-fidelity Q5 polymerase (see
Table S16 at https://doi.org/10.5281/zenodo.3784407). PCR products were analyzed by gel electropho-
resis. The Zero Blunt PCR cloning kit was used to clone PCR fragments, and 20 positive clones were
sequenced. A BLASTn search against the NCBI nucleotide database showed “Nocardia araoensis NBRC
100135” as the first hit for all 20 clones. In addition, production cultures were examined visually by
microscopy and inoculation of selective media. No contamination could be observed.
Mycobactin-like siderophore structure elucidation. NMR solvents were obtained from Sigma-
Aldrich and used without further purification.
For NMR analysis, 1.5 mg gallium sulfate was dissolved in 3 ml deuterated methanol and then
incubated with the mycobactin-like siderophore overnight. The solvent was removed in vacuo, and the
Ga-bound species was resuspended in CDCl3 for NMR analyses. Chemical shift signals () are reported in
parts per million and are referenced to the internal chloroform signal ( 7.26 ppm for 1H;  77.2 ppm
for 13C).
LC-HRMS and MS/MS analysis. High-resolution mass spectra (HRMS) were collected on an
Agilent 6530 Accurate-Mass Quadrupole Time-of-flight (QTOF) LC-MS instrument (Agilent Technol-
ogies) with an electrospray ionization (ESI) interface. Ten to 15 l of each crude extract was injected
onto a reversed-phase C18 column [Phenomenex Luna 5-m C18(2) column [4.6 150 mm; 100 Å])
on a 1260 Infinity LC-System (Agilent Technologies) using a flow rate of 0.75 ml/min to separate the
analytes. MS analysis was performed by ESI in positive ionization mode (50 eV). A gradient from 80%
solvent A (water with 0.1% formic acid) to 97% solvent B (acetonitrile [ACN] with 0.06% formic acid)
was applied.
Global Natural Products Social Molecular Networking (GNPS) molecular MS/MS network. A
molecular network was created to simplify the discovery of new nocobactin and mycobactin derivatives
using the online workflow at Global Natural Products Social Molecular Networking (GNPS) (59). High-
resolution LC-MS data were converted to .mzxml format using MSConvert version 3.0.18353-2de7e414e.
The data were clustered with MS-Cluster with a parent ion mass tolerance of 0.04 Da and a fragment ion
mass tolerance of 0.04 Da to create consensus spectra. Networks were created where edges were filtered
to have a cosine score above 0.6 and more than three matched peaks. A peak intensity of 50 was set as
minimum peak intensity. The resulting molecular network was visualized in Cytoscape 3.6.1 (68). The
MS/MS data were deposited in MassIVE (MSV000084771) and linked with the genomic data at the
iOMEGA Pairing Omics Data Platform (http://pairedomicsdata.bioinformatics.nl/projects).
Stable isotope labeling. For feeding experiments with L-[1-13C]serine, labeled substrates were
added after 2 days of cultivation in a 5 mM final concentration, respectively. High-resolution mass spectra
for feeding experiments as well as nocobactin-like siderophore metabolomics data from Nocardia
cyriacigeorgica GUH-2 were recorded on an HR-ESI-TOF-MS maXis 4G mass spectrometer (Bruker Daltonik
GmbH, Bremen, Germany).
Statistical analysis. BiG-SCAPE annotations were used to compute the BGC class frequency for all
the Nocardia genomes. The statistical significance for differences in the BGC class frequency between
group 1 pathogens and other Nocardia genomes was calculated using t test in Rstudio version 1.1.383.
Boxplots were generated in Rstudio using the package ggpubr version 0.2.5 and ggplot2. BiG-SCAPE
presence/absence matrix containing information on gene cluster families (GCFs) across all the Nocardia
genomes was used to perform principal-component analysis (PCA) using ClustVis web tool.
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Tables 
Table S 1: gradient for preparative HPLC. 
time [min] solvent A [%] solvent B [%] 
0 75 25 
3 75 25 
6 50 50 
11 1 99 
20 1 99 
25 75 25 
30 75 25 
 
Table S 2: gradient for analytical HPLC. 
time [min] solvent A [%] solvent B [%] 
0 75 25 
3 75 25 
6 50 50 
11 1 99 
20 1 99 
22 75 25 
25 75 25 
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Table S 3: genes considered in autoMLST phylogenetic tree. 
 
 
  
protein family gene associated function associated enzyme
TIGR01798 cit_synth_I Energy metabolism citrate (Si)-synthase
TIGR00043 TIGR00043 Protein synthesis rRNA maturation RNase YbeY
TIGR00970 leuA_yeast Amino acid biosynthesis 2-isopropylmalate synthase
TIGR01855 IMP_synth_hisH Amino acid biosynthesis imidazole glycerol phosphate synthase, glutamine amidotransferase subunit
TIGR00115 tig Protein fate trigger factor
TIGR00138 rsmG_gidB Protein synthesis 16S rRNA (guanine(527)-N(7))-methyltransferase RsmG
TIGR01978 sufC Biosynthesis of cofactors, prosthetic groups, and carriers FeS assembly ATPase SufC
TIGR02673 FtsE Cellular processes cell division ATP-binding protein FtsE
TIGR00338 serB Amino acid biosynthesis phosphoserine phosphatase SerB
TIGR00154 ispE Biosynthesis of cofactors, prosthetic groups, and carriers 4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol kinase
TIGR00031 UDP-GALP_mutase Cell envelope UDP-galactopyranose mutase
TIGR00922 nusG Transcription transcription termination/antitermination factor NusG
TIGR02091 glgC Energy metabolism glucose-1-phosphate adenylyltransferase
TIGR03723 T6A_TsaD_YgjD Protein synthesis tRNA threonylcarbamoyl adenosine modification protein TsaD
TIGR00158 L9 Protein synthesis ribosomal protein bL9
TIGR01083 nth DNA metabolism endonuclease III
TIGR00090 rsfS_iojap_ybeB Protein synthesis ribosome silencing factor
TIGR00091 TIGR00091 Protein synthesis tRNA (guanine-N(7)-)-methyltransferase
TIGR02692 tRNA_CCA_actino Protein synthesis CCA tRNA nucleotidyltransferase
TIGR01072 murA Cell envelope UDP-N-acetylglucosamine 1-carboxyvinyltransferase
TIGR00190 thiC Biosynthesis of cofactors, prosthetic groups, and carriers phosphomethylpyrimidine synthase
TIGR00096 TIGR00096 Protein synthesis 16S rRNA (cytidine(1402)-2'-O)-methyltransferase
TIGR00218 manA Energy metabolism mannose-6-phosphate isomerase, class I
TIGR01737 FGAM_synth_I Purines, pyrimidines, nucleosides, and nucleotides phosphoribosylformylglycinamidine synthase I
TIGR01994 SUF_scaf_2 Biosynthesis of cofactors, prosthetic groups, and carriers SUF system FeS assembly protein, NifU family
TIGR03800 PLP_synth_Pdx2 Biosynthesis of cofactors, prosthetic groups, and carriers pyridoxal 5'-phosphate synthase, glutaminase subunit Pdx2
TIGR00963 secA Protein fate preprotein translocase, SecA subunit
TIGR00964 secE_bact Protein fate preprotein translocase, SecE subunit
Ribosomal_L10 PF00466.16 Unclassified Ribosomal protein L10
TIGR01280 xseB DNA metabolism exodeoxyribonuclease VII, small subunit
TIGR00168 infC Protein synthesis translation initiation factor IF-3
TIGR00731 bL25_bact_ctc Protein synthesis ribosomal protein bL25, Ctc-form
TIGR02727 MTHFS_bact Central intermediary metabolism 5-formyltetrahydrofolate cyclo-ligase
TIGR01966 RNasePH Transcription ribonuclease PH
TIGR00382 clpX Protein fate ATP-dependent Clp protease, ATP-binding subunit ClpX
TIGR01357 aroB Amino acid biosynthesis 3-dehydroquinate synthase
TIGR02729 Obg_CgtA Protein synthesis Obg family GTPase CgtA
TIGR01683 thiS Biosynthesis of cofactors, prosthetic groups, and carriers thiamine biosynthesis protein ThiS
TIGR00020 prfB Protein synthesis peptide chain release factor 2
TIGR00751 menA Biosynthesis of cofactors, prosthetic groups, and carriers 1,4-dihydroxy-2-naphthoate octaprenyltransferase
TIGR03534 RF_mod_PrmC Protein fate protein-(glutamine-N5) methyltransferase, release factor-specific
TIGR01393 lepA Unknown function elongation factor 4
TIGR00564 trpE_most Amino acid biosynthesis anthranilate synthase component I
TIGR00759 aceE Unclassified pyruvate dehydrogenase (acetyl-transferring), homodimeric type
TIGR00302 TIGR00302 Purines, pyrimidines, nucleosides, and nucleotides phosphoribosylformylglycinamidine synthase, purS protein
TIGR00330 glpX Energy metabolism fructose-1,6-bisphosphatase, class II
TIGR00237 xseA DNA metabolism exodeoxyribonuclease VII, large subunit
TIGR00613 reco DNA metabolism DNA repair protein RecO
TIGR01498 folK Biosynthesis of cofactors, prosthetic groups, and carriers 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase
TIGR00713 hemL Biosynthesis of cofactors, prosthetic groups, and carriers glutamate-1-semialdehyde-2,1-aminomutase
TIGR00525 folB Biosynthesis of cofactors, prosthetic groups, and carriers dihydroneopterin aldolase
TIGR00615 recR DNA metabolism recombination protein RecR
TIGR00362 DnaA DNA metabolism chromosomal replication initiator protein DnaA
TIGR01980 sufB Biosynthesis of cofactors, prosthetic groups, and carriers FeS assembly protein SufB
TIGR01051 topA_bact DNA metabolism DNA topoisomerase I
TIGR00082 rbfA Transcription ribosome-binding factor A
TIGR01039 atpD Energy metabolism ATP synthase F1, beta subunit
TIGR00739 yajC Protein fate preprotein translocase, YajC subunit
TIGR03284 thym_sym Purines, pyrimidines, nucleosides, and nucleotides thymidylate synthase
TIGR01137 cysta_beta Amino acid biosynthesis cystathionine beta-synthase
TIGR00103 DNA_YbaB_EbfC Unknown function DNA-binding protein, YbaB/EbfC family
TIGR01032 rplT_bact Protein synthesis ribosomal protein bL20
TIGR01296 asd_B Amino acid biosynthesis aspartate-semialdehyde dehydrogenase
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Table S 4: A-domain analysis of NRPS gene encoded in GCF 4. 
  
GCF 4 A1 AA A2 AA A3 AA A4 AA 
N. farcinica DVWHFSXX S DALFIGMV - DALFMGAI F/W DALFLGVI Hpg 
N. brasiliensis DVWHFSLV S DALFIGMV - DALFMGGI F/W DALALGVI Hpg 
N. abscessus DVWHFSLV S DALFIGMV - DALFMGVV F/W ? ? 
N. otitidiscaviarum DVWHFSLV S DALFIGMV - DAFFMGGV L/I/V DALFLGVI Hpg 
N. kruczakiae DVWHFSLV S DALFIGMV - DALFMGGI F/W DALFLGVI Hpg 
N. asteroides DVWHFSLV S DALFIGMV - DVLFMGAV - DGLFLGVI L 
N. brevicatena DVWHFSLV S DALFMGMV - DALFMGVI F/W DALFLGAI F/W 
N. nova DVWHFSLV S DALFIGMV - DALFMGGI F/W DALFLGVI Hpg 
N. cyriacigeorgica DVWHFSLV S DALFMGMV - DALFMGVV F/W DALALGVI Hpg 
N. transvalensis DVWHFSLV S DALFIGMV - DAFFVGGV V DALFLGVI Hpg 
N. veterana DVWHFSLV S DALFIGMV - DALFMGGI F/W DALFLGVI Hpg 
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Table S 5: MS properties of terpenibactin A, B and C produced by Nocardia terpenica IFM 0406. 
 
 
Table S 6: MS properties of putative siderophores produced by Nocardia araoensis NBRC 100135. 
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Table S 7: MS properties of putative siderophores produced by Nocardia takedensis NBRC 100417. 
 
Table S 8: MS properties of putative siderophores produced by Nocardia jejuensis NBRC 103114. 
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Table S 9: MS properties of putative siderophores produced by Nocardia fusca NBRC 14340. 
 
Table S 10: MS properties of putative siderophore produced by Nocardia rhamnosiphila NBRC 108938. 
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Table S 11: MS properties of putative siderophores produced by Nocardia vermiculata NBRC 100427. 
 
Table S 12: MS properties of putative siderophores produced by N. gamkensis NBRC 108242. 
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Table S 13: MS properties of putative siderophores produced by Nocardia elegans NBRC 108235. 
 
 
Table S 14: MS properties of putative siderophores produced by Nocardia alba NBRC 108234. 
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Table S 15: MS properties of putative siderophores produced by Nocardia cyriacigeorgica GUH-2. 
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Table S 16: PCR Primers. 
Primer name Primer sequence 5’ → 3’ 
27F AGAGTTTGATCMTGGCTCAG 
1492R GGTTACCTTGTTACGACTT 
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Table S 17: NMR spectroscopic data of a mycobactin-like siderophore from N. araoensis NBRC 100135. 
Mycobactin-like siderophore incubated with gallium sulphate in CD3OD, concentrated in vacuo, then NMR data 
recorded in CDCl3. Numbering scheme adapted from Hoshino et al. 2011.1 
 
 
Assignment 1H-NMR 13C-NMR Number 
phenol 
H-3 6.59 115.4 3 
H-4 7.32 135.9 4 
H-5 6.92 122.8 5 
H-6 7.60 129.6 6 
oxazoline 
H-9 4.84, 4.61 70.7 9 
H-10 4.62 66.8 10 
Lys1 (linear) 
NH 7.95 - 13 
α 4.69 50.3 14 
β 2.13 30.3 28 
γ 1.32 29.8 29 
δ 2.00, 1.87 27.3 30 
ε 4.04, 3.84 53.4 31 
3-hydroxybutanoate 
α 2.82, 2.45 41.8 18 
β 5.50 67.6 17 
γ 1.38 18.4 33 
Lys2 (cyclic) 
NH 9.75 - 20 
α 4.32 53.7 21 
β 2.12, 2.09 26.6 27 
γ 1.87, 1.55 27.1 26 
δ 1.82, 1.57 18.3 25 
ε 3.96, 3.74 48.4 24 
Fatty acid 
C=O - 165.1 1’ 
H-2’ 2.49, 2.33 29.5 2’ 
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H-3’ 1.78 25.7 3’ 
H-4’ to H-11’ 1.29 (multiple) 29.8 (multiple) 4’-11’ 
H-12’ 1.27 32.1 12’ 
H-13’ 1.30 22.8 13’ 
H-14’ 0.89 14.1 14’ 
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Table S 18: Gene cluster table of nocobactin-like BGC from N. araoensis NBRC 100135. 
gene AA protein homolog accession number ID predicted function 
nbtS 436 salicylate synthase [Nocardia 
farcinica IFM 10152] 
BAD55464.1 87.7 salicylate synthase 
nbtT 538 putative salicylate-AMP ligase 
[Nocardia farcinica IFM 10152] 
BAD55465.1 84.56 salicylate-AMP ligase 
nbtG 428 putative lysine-N-oxygenase 
[Nocardia farcinica IFM 10152] 
BAD55606.1 79.43 lysine-N-oxygenase 
nbtH 220 putative N6-hydroxylysine 
acetyltransferase [Nocardia 
farcinica IFM 10152] 
BAD55607.1 58.41 N6-hydroxylysine 
acetyltransferase 
nbtA 257 thioesterase [Nocardia farcinica 
IFM 10152] 
BAD55608.1 62.55 thioesterase 
nbtB 442 putative polyketide synthase 
[Nocardia farcinica IFM 10152] 
BAD55609.1 72.54 polyketide synthase 
nbtC 1011 putative polyketide synthase 
[Nocardia farcinica IFM 10152] 
BAD55610.1 55.11 polyketide synthase 
nbtD 1508 non-ribosomal peptide 
synthethase [Nocardia farcinica 
IFM 10152] 
BAD55612.1 58.6 non-ribosomal peptide 
synthethase 
nbtE 1671 putative non-ribosomal peptide 
synthethase [Nocardia farcinica 
IFM 10152] 
BAD55611.1 57.22 non-ribosomal peptide 
synthethase 
nbtX 360 putative membrane protein 
[Nocardia farcinica IFM 10152] 
BAD60682.1 35.82 Unknown/ hypothetical 
protein 
nbtF 958 putative non-ribosomal peptide 
synthethase [Nocardia farcinica 
IFM 10152] 
BAD55613.1 81.31 non-ribosomal peptide 
synthethase 
*Abbreviations 
AA protein length in amino acid 
ID amino acid identity [%] 
Sim amino acid similarity 
N. Nocardia 
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Table S 19: Nocardia strains used for metabolic analysis. 
genome GenBank accession number Source of Isolation Biosafety level 
Nocardia araoensis NBRC 100135 BAFR00000000 Human 1 
Nocardia cyriacigeorgica GUH-2 NC_016887 human 2 
Nocardia takedensis NBRC 100417 NZ_BAGG00000000 Human 1 
Nocardia sp. Root136 NZ_LMFE00000000 Soil 1 
Nocardia jejuensis NBRC 103114 NZ_BDBU00000000 Human 1 
Nocardia fusca NBRC 14340 NZ_BDCU00000000 Freshwater 1 
Nocardia rhamnosiphila NBRC 108938 NZ_BDCL00000000 Animal 1 
Nocardia vermiculata NBRC 100427 NZ_BDCA00000000 Soil 1 
Nocardia gamkensis NBRC 108242 NZ_BDBM00000000 Soil 1 
Nocardia elegans NBRC 108235 NZ_BDBF00000000 Human 1 
Nocardia alba NBRC 108234 NZ_BDAX00000000 plant 1 
Nocardia seriolae DSM 44129 n.a. animal 1 
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Table S 20: checkM analysis on Nocardia genomes used in this study. 
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Table S 21: Analysis of putative virulence factors in Nocardia spp.. 
Genes for catalases and superoxide dismutases were manually searched by hmmsearch (HMMER 3.1b2). Catalases 
included searches for Catalase, Mn_catalase Catalase-rel, Catalase_C, HTHP and Peroxidase Hidden Markov Models. 
Superoxide Dismutases (SoDs) included searches for Sod_Cu, Sod_Fe_C, Sod_Fe_N and Sod_Ni Hidden Markov 
Models. Virulence factor counts were in accordance with Vera-Cabrera et al. 2013.2 
 
strain source of isolation catalases SoDs number of BGCs autoMLST clade genome size [Mbp]
Mycobacterium tuberculosis  H37Rv human 1 2 15 n.a. 4.4
Nocardia abscessus  NBRC 100374 human 5 2 46 A 8.4
Nocardia acidivorans  NBRC 108247 soil 3 2 37 F 7.6
Nocardia africana  NBRC 100379 human 6 2 30 E 7.8
Nocardia alba  NBRC 108234 soil 3 2 32 D 7.3
Nocardia altamirensis  NBRC 108246 soil n.a. n.a. 57 A 9.8
Nocardia amamiensis NBRC 102102 soil 3 2 45 A 8.2
Nocardia amikacinitolerans  DSM 45535 human 3 2 32 B 7.3
Nocardia amikacinitolerans  DSM 45536 human 4 2 30 B 7.5
Nocardia amikacinitolerans  DSM 45537 human 4 2 31 B 7.4
Nocardia amikacinitolerans  DSM 45538 human 4 2 31 B 7.6
Nocardia amikacinitolerans  NBRC 108937 human 4 2 30 B 7.6
Nocardia anaemiae  NBRC 100462 human 5 2 46 A 8.6
Nocardia aobensis  NBRC 100429 human 4 2 43 E 7.5
Nocardia araoensis  NBRC 100135 human 4 2 45 A 7.7
Nocardia arthritidis  NBRC 100137 human 5 2 44 A 7.1
Nocardia asiatica  NBRC 100129 human 5 2 56 A 8.5
Nocardia asteroides  DSM 43373 human 3 2 30 D 7.0
Nocardia asteroides  NBRC 15531 soil 3 2 30 D 7.0
Nocardia beijingensis  NBRC 16342 soil 4 2 43 A 7.5
Nocardia brasiliensis  ATCC 700358 human 5 2 49 A 9.4
Nocardia brasiliensis  IFM 10847 human 5 2 56 A 9.2
Nocardia brasiliensis  NBRC 14402 human 6 2 49 A 8.9
Nocardia brevicatena  NBRC 12119 human 3 2 35 C 7.0
Nocardia caishijiensis  NBRC 108228 soil 2 2 28 D 6.3
Nocardia carnea  NBRC 14403 human 3 2 29 C 7.5
Nocardia cerradoensis  NBRC 101014 soil 5 2 50 E 7.6
Nocardia concava  NBRC 100430 human 4 2 51 F 8.9
Nocardia coubleae  NBRC 108252 soil 3 2 31 D 6.6
Nocardia crassostreae  NBRC 100342 animal 3 2 41 F 8.3
Nocardia cummidelens  NBRC 100378 plant 3 2 30 D 7.5
Nocardia cyriacigeorgica  GUH-2 human 3 2 22 C 6.2
Nocardia cyriacigeorgica  NBRC 100375 human 4 3 35 C 6.3
Nocardia donostiensis  X1655 human 4 2 29 C 5.8
Nocardia elegans  NBRC 108235 human 3 2 36 E 7.5
Nocardia exalbida  NBRC 100660 human 5 2 44 A 7.4
Nocardia farcinica  DSM 43257 human 5 2 23 B 6.4
Nocardia farcinica  IFM 10152 human 4 2 17 B 6.3
Nocardia farcinica  NCTC 11134 animal 5 2 19 B 6.5
Nocardia flavorosea  NBRC 108225 soil 3 3 25 C 7.4
Nocardia fluminea  DSM 44489 freshwater 2 2 32 D 8.1
Nocardia fusca  NBRC 14340 soil 4 2 32 C 8.0
Nocardia gamkensis  NBRC 108242 soil 4 2 37 A 7.7
Nocardia grenadensis  NBRC 108939 soil 3 2 29 C 6.5
Nocardia harenae  NBRC 108248 soil 3 2 26 X 6.1
Nocardia higoensis  NBRC 100133 human 2 2 28 B 7.0
Nocardia ignorata  NBRC 108230 human 3 2 32 D 7.0
Nocardia inohanensis  NBRC 100128 human 6 2 42 F 8.1
Nocardia jiangxiensis  NBRC 101359 soil 5 3 38 E 10.4
Nocardia jinanensis  NBRC 108249 soil 4 3 29 C 5.0
Nocardia kruczakiae  NBRC 101016 human 4 2 36 E 7.3
Nocardia lijiangensis  NBRC 108240 soil 4 2 47 B 8.2
Nocardia mexicana  NBRC 108244 human 4 2 43 E 9.0
Nocardia mikamii  NBRC 108933 human 4 2 36 E 7.6
Nocardia miyunensis  NBRC 108239 soil 9 2 41 E 10.5
Nocardia niigatensis  NBRC 100131 human 4 2 33 F 8.2
Nocardia niwae  NBRC 108934 human 4 2 40 A 7.3
Nocardia nova  SH22a plant 3 2 30 E 8.3
Nocardia otitidiscaviarum  IFM 11049 human 5 3 31 F 7.9
Nocardia otitidiscaviarum  NBRC 14405 animal 6 3 33 F 7.5
Nocardia paucivorans  NBRC 100373 human 5 2 30 C 6.0
Nocardia pneumoniae  NBRC 100136 human 4 2 41 A 7.6
Nocardia pseudobrasiliensis  IFM 0761 human 4 3 51 E 8.3
Nocardia pseudovaccinii  NBRC 100343 soil 4 2 56 A 9.9
Nocardia puris  NBRC 108233 human 3 2 38 B 7.7
Nocardia rhamnosiphila  NBRC 108938 soil 3 2 40 C 7.7
Nocardia salmonicida  NBRC 13393 animal 3 2 33 D 8.3
Nocardia seriolae  N-2927 animal 2 2 36 F 7.7
Nocardia seriolae  U-1 animal 2 2 30 F 7.7
Nocardia seriolae  ZJ0503 animal 2 2 31 F 7.7
Nocardia shimofusensis  NBRC 100134 soil 2 2 23 B 6.3
Nocardia sienata  NBRC 100364 human 4 2 38 C 6.8
Nocardia soli  NBRC 100376 freshwater 3 2 32 D 7.6
Nocardia  sp. 852002-20019_SCH5090214 ? 4 2 35 E 8.3
Nocardia  sp. 852002-51101_SCH5132738 ? 4 2 35 E 7.7
Nocardia  sp. 852002-51244_SCH5132740 ? 4 2 36 E 7.7
Nocardia  sp. BMG 111209 plant 3 2 29 F 9.1
Nocardia  sp. BMG 51109 plant 4 2 45 E 8.8
Nocardia  sp. CNS044 marine 5 2 35 B 7.4
Nocardia  sp. CNY236 marine 2 2 38 A 5.3
Nocardia  sp. NRRL WC-3656 soil 3 2 41 E 7.3
Nocardia  sp. Root136 plant 3 2 30 D 7.3
Nocardia  sp. W9405 human 2 2 32 B 7.2
Nocardia speluncae  NBRC 108251 soil 5 2 24 C 7.4
Nocardia takedensis  NBRC 100417 soil 3 2 35 B 8.0
Nocardia tenerifensis  NBRC 101015 soil 5 3 71 A 9.7
Nocardia terpenica  IFM 0406 human 4 2 48 E 9.3
Nocardia terpenica  NBRC 100888 human 4 2 18 E 8.6
Nocardia testacea  NBRC 100365 human 4 2 29 C 7.3
Nocardia thailandica  NBRC 100428 human 3 2 33 D 6.8
Nocardia transvalensis  NBRC 15921 human 4 2 36 D 8.4
Nocardia uniformis  NBRC 13702 soil 4 2 36 F 8.8
Nocardia vaccinii  NBRC 15922 plant 3 2 31 E 9.2
Nocardia vermiculata  NBRC 100427 human 4 2 28 E 6.7
Nocardia veterana  NBRC 100344 human 4 2 29 E 6.8
Nocardia vinacea  NBRC 16497 soil 6 2 61 A 10.2
Nocardia violaceofusca  NBRC 14427 soil 4 2 35 E 7.5
Nocardia vulneris  W9851 human 6 2 46 A 9.3
Nocardia xishanensis  NBRC 101358 soil 5 2 27 B 7.7
Nocardia yamanashiensis  NBRC 100130 human 3 2 49 F 9.1
Nocardia jejuensis  NBRC 103114 soil 4 2 37 F 8.7
Nocardia  sp. LAM0056 soil 3 2 22 C 6.2
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Table S 22: Presence/absence map of N. farcinica IFM 10152 BGCs in group 1 pathogens.  
Putative antiSMASH (4.0.0) BGCs from Nocardia farcinica IFM 10152 were used as reference to manually analyze 
the BGC content of the other group 1 Nocardia strains. Presence/ absence in other Nocardia was marked in color, 
when a homologous BGC was found. Color indicates BGC cluster types: Light yellow (type I pks), dark blue (other), 
purple (terpene), dark green (nrps), dark yellow (arylpolyene), light green (ectoine), light blue (type I pks-nrps). 
 
 
 
antiSMASH 4.0.0 predicted BGCs
group 1 pathogen 1 2 3a 3b 3c 4 5 6 7 8 9 10 11 12 13 14 15 16a 16b 16c
N. farcinica  IFM 10152
N. cyriacigeorgica  GUH-2
N. asteroides  NBRC 15531
N. nova  SH22a
N. otitidiscaviarum  NBRC 14405
N. abscessus  NBRC 100374
N. brasiliensis  IFM 10847
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Figures 
 
Figure S 1: Genome size plotted against the number of predicted BGCs in Nocardia strains. 
Each dot corresponds to one Nocardia strain. Colors indicate phylogenetic clade A-F and X. Trendline indicates a 
positive correlation between number of BGCs present in a strain and its genome size (coefficient of determination 
(R2=0.4057). 
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Figure S 2: Nocardia maximum likelihood autoMLST tree. 
Analysis of 104 genomes obtained from JGI specified as Nocardia based on 63 concatenated housekeeping genes 
identified with autoMLST. Ultrafast bootstrap values were calculated using 1000 replicates. Mycobacterium fallax 
DSM 44179 and Gordonia bronchialis DSM 43247 were used as outgroups.
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Figure S 3: Terpenibactins A-C produced by N. terpenica IFM 0406. 
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Figure S 4: MS/MS analysis of terpenibactin A. 
Precursor mass (882.4135 [M-2H+Ga]+) is marked with a blue diamond. 
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Figure S 5: MS/MS analysis of a putative mycobactin-like siderophore with 824.3353 [M-2H+Ga]+ produced by Nocardia araoensis NBRC 100135. 
Precursor mass is marked with a blue diamond. 
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Figure S 6: MS/MS analysis of a putative mycobactin-like siderophore with 840.3669 [M-2H+Ga]+ produced by Nocardia araoensis NBRC 100135. 
Precursor mass is marked with a blue diamond.  
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Figure S 7: MS/MS analysis of 854.3817 [M-2H+Ga]+ produced by Nocardia takedensis NBRC 100417. 
Precursor mass is marked with a blue diamond. 
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Figure S 8: MS/MS analysis of putative nocardimicin G with 840.3676 [M-2H+Ga]+ produced by Nocardia jejuensis NBRC 103114. 
Precursor mass is marked with a blue diamond. 
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Figure S 9: MS/MS analysis of 812.3442 [M-2H+Ga]+ produced by Nocardia fusca NBRC 14340. 
Precursor mass is marked with a blue diamond. 
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Figure S 10: MS/MS analysis of 812.3352 [M-2H+Ga]+ produced by Nocardia rhamnosiphila NBRC 108938. 
Precursor mass is marked with a blue diamond. 
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Figure S 11: MS/MS analysis of 840.3685 [M-2H+Ga]+ produced by Nocardia vermiculata NBRC 100427. 
Precursor mass is marked with a blue diamond. 
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Figure S 12: MS/MS analysis of putative formobactin with 810.3192 [M-2H+Ga]+ produced by Nocardia gamkensis NBRC 108242. 
Precursor mass is marked with a blue diamond. 
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Figure S 13: MS/MS analysis of putative carboxynocobactin with 812.2634 [M-2H+Ga]+ produced by Nocardia gamkensis NBRC 108242. 
Precursor mass is marked with a blue diamond. 
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Figure S 14: MS/MS analysis of putative carboxynocobactin with 840.2954 [M-2H+Ga]+ produced by Nocardia gamkensis NBRC 108242. 
Precursor mass is marked with a blue diamond. 
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Figure S 15: MS/MS analysis of putative nocardimicin G with 840.3683 [M-2H+Ga]+ produced by Nocardia elegans NBRC 108235. 
Precursor mass is marked with a blue diamond. 
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Figure S 16: MS/MS analysis of putative nocardimicin H with 868.3985 [M-2H+Ga]+ produced by Nocardia elegans NBRC 108235. 
Precursor mass is marked with a blue diamond. 
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Figure S 17 MS/MS analysis of 810.3227 [M-2H+Ga]+ produced by Nocardia alba NBRC 108234. 
Precursor mass is marked with a blue diamond. 
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Figure S 18: MS/MS analysis of putative nocardimicin A with 796.3046 [M-2H+Ga]+ produced by Nocardia alba NBRC 108234. 
Precursor mass is marked with a blue diamond. 
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Figure S 19: MS/MS analysis of putative nocardimicin B with 824.3355 [M-2H+Ga]+ produced by Nocardia alba NBRC 108234. 
Precursor mass is marked with a blue diamond.  
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Figure S 20: MS/MS analysis of putative nocardimicin D with 852.3668 [M-2H+Ga]+ produced by Nocardia alba NBRC 108234.  
Precursor mass is marked with a blue diamond.  
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Figure S 21: MS/MS analysis of putative brasilibactin A with 868.3989 [M-2H+Ga]+ produced by Nocardia cyriacigeorgica GUH-2.  
Precursor mass is marked with a blue diamond. 
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Figure S 22: BiG-SCAPE cluster-type sequence similarity network of all nocobactin-type BGCs from Nocardia strains found with antiSMASH 4.0.  
A BiG-SCAPE threshold of 70 % is shown without singletons. Nocobactin-like BGCs and respective cluster parts II (nbtS/nbtT) were trimmed manually and concatenated. Bold circles 
highlighted show strains cultivated for metabolomics studies. Numbers represent strain identification numbers. Filling colors represent phylogenetic clades A-F.
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(1) Isotopic peak analysis of 838.3512 [M-2H+Ga]+ non-supplemented cultures 
 
(2) Isotopic peak analysis of 839.3540 [M-2H+Ga]+ from L-serine-1-13C-supplemented cultures 
 
Figure S 23: Isotopic peak analysis of unlabeled and 13C-labeled nocobactin-like siderophore. 
Isotopic peak analysis of Nocardia alba NBRC 108234 extracts; (1) unfed Nocardia alba produces unlabeled 
nocobactin-like siderophore 838.3512 [M-2H+Ga]+; feeding Nocardia alba with 13C1-labeled L-serine 
results in m/z shifts of 839.3540 [M-2H+Ga+1]+, 840.3561 [M-2H+Ga+2]+, 841.3546 [M-2H+Ga+3]+, 
842.3574 [M-2H+Ga+4]+, 843.3618 [M-2H+Ga+5]+. 
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(1) MS/MS analysis of an unlabeled nocobactin-like siderophore; precursor ion m/z 838.3608 [M-2H+Ga]+ 
 
(2) MS/MS analysis of a L-serine-1-13C labeled nocobactin-like siderophore; precursor mass ion m/z 839.5489 [M-2H+Ga+1]+ 
 
Figure S 24: MS/MS analysis of a 13C-labeled/ unlabeled nocobactin-like siderophore from Nocardia alba NBRC 108234.  
Labeled 13C is marked in green. Precursor mass is marked with a blue diamond. 
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Figure S 25: TOCSY correlations and key HMBC correlations of a mycobactin-type siderophore with m/z 
840.3669 [M+Ga-2H]+. 
 
 
Figure S 26: 1H NMR spectrum of a gallium-bound mycobactin-like siderophore with m/z 840.3669 
[M+Ga-2H]+ from Nocardia araoensis NBRC 100135 in CDCl3 (600 MHz). 
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Figure S 27: 1H-13C multiplicity edited HSQC NMR spectrum of gallium-bound mycobactin-like 
siderophore from Nocardia araoensis NBRC 100135 in CDCl3 (600 MHz) with m/z 840.3669 [M+Ga-2H]+. 
  
 
 
 
Figures 
49 
 
 
Figure S 28: 1H-1H TOCSY NMR spectrum of gallium-bound mycobactin-like siderophore from Nocardia 
araoensis NBRC 100135 in CDCl3 (600 MHz) with m/z 840.3669 [M+Ga-2H]+. 
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Figure S 29: 1H-13C HMBC NMR spectrum of gallium-bound mycobactin-like siderophore from Nocardia 
araoensis NBRC 100135 in CDCl3 (600 MHz) with m/z 840.3669 [M+Ga-2H]+. 
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Figure S 30: Nocardia autoMLST tree. Colors indicate Nocardia spp. source of isolation. Information 
regarding isolation source was taken from respective published genomes. 
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Figure S 31: BiG-SCAPE cluster type sequence similarity network of all BGCs from Nocardia strains found 
with antiSMASH 4.0 including the MIBiG database.  
Colors show cluster types from Nocardia BGCs. Colorless nodes are hybrid BGCs found in Nocardia. Bold 
node borders refer to group 1 pathogens. MIBiG BGCs (version 1.4) were hidden when no Nocardia BGC 
showed a similarity. 
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Figure S 32: Number of contigs plotted against the number of predicted BGCs in Nocardia strains. 
Each dot corresponds to one Nocardia strain. Trendline indicates no correlation between number of 
BGCs present in a strain and its genome size (coefficient of determination (R2=0.2821). 
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Figure S 33: Boxplot of BGC class frequency distribution across Nocardia genome groups. 
Group1: Group 1 pathogenic Nocardia. Other: “other” Nocardia in analysis not in group 1 pathogens. X-axis 
represents BiG-SCAPE groups across Nocardia natural product classes. Y-axis represents total numbers of BGC-class 
frequencies. Black bars within boxplots show median BGC-class frequencies. Black dots represent outliners. Red/blue 
lines show whiskers of respective groups. Box edges represent lower and upper quartile. For identifying the group 1 
individual genome specific clusters, a raw distance (cutoff = 0.75) was used as given in BiG-SCAPE network matrices. 
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Figure S 34: PCA-analysis on GCF presence/absence. 
GCF presence/absence information for clustering the Nocardia genomes into separate groups based on clinical 
annotations (Nocardia group 1 pathogens: 1 = Nocardia abscessus NBRC 100374; 5 = Nocardia asteroides NBRC 
15531; 6 = Nocardia brasiliensis ATCC 700358; 13 = Nocardia cyriacigeorgica GUH-2; 16 = Nocardia farcinica IFM 
10152; 21 = Nocardia otitidiscaviarum NBRC 14405; 47 = Nocardia nova SH22a (NONO); “other” Nocardia genomes 
not in group). X and Y axis show principal component 1 (PC1) and principal component 2 (PC2) that explain 3.2 % and 
2.6 % of the total variance, respectively. Sample size = 107 data points. Genome analysis IDs are annotated along-
side the data points. The PCA plot was performed using ClustVis web tool. 
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New Nocobactin Derivatives with Antimuscarinic Activity,
Terpenibactins A–C, Revealed by Genome Mining of
Nocardia terpenica IFM 0406
Julia Chen,[a, b] Andri Frediansyah,[a, b, c] Daniel Männle,[a, b, d] Jan Straetener,[b, e]
Heike Brötz-Oesterhelt,[b, e] Nadine Ziemert,[b, d] Leonard Kaysser,[a, b] and Harald Gross*[a, b]
We report a genomics-guided exploration of the metabolic
potential of the brasilicardin producer strain Nocardia terpenica
IFM 0406. Bioinformatics analysis of the whole genome
sequence revealed the presence of a biosynthetic gene cluster
presumably responsible for the generation of formerly unknown
nocobactin derivatives. Mass spectrometry-assisted isolation led
to the identification of three new siderophores, terpenibactins
A (1), B (2) and C (3), which belong to the class of nocobactins.
Their structures were elucidated by employing spectroscopic
techniques. Compounds 1–3 demonstrated inhibitory activity
towards the muscarinic M3 receptor, while exhibiting only a
low cytotoxicity.
Introduction
In the past, bacteria of the genus Nocardia were principally
associated with a pathogenic context, having been described in
1888 by Edwin Nocard[1] as the causative agent of severe
infections of the skin, lungs or the central nervous system in
humans and animals.[2,3] However, within the last two decades,
it has become apparent that this genus also possesses a
tremendous biotechnological and pharmaceutical potential,
with species that produce numerous versatile enzymes[4–6] and
structurally novel and highly bioactive small molecules.[7,8] This
observation is also supported by analyses of the ever-increasing
amount of publicly available Nocardia genome sequencing
data.[9–12] Commonly, Nocardia spp. genomes comprise 16 to 49
biosynthetic gene clusters, which is why Nocardia spp. are
considered ‘biosynthetically talented’ producers.
A prime example of such is the strain Nocardia terpenica IFM
0406 (formerly referred to as Nocardia brasiliensis IFM 0406).[13] It
is known to produce the anti-staphylococcal lipolanthine
nocavionin,[14] the antifungal brasilinolides[15–17] and the immu-
nosuppressive brasilicardins.[18–21] In order to develop a safe
biotechnological production platform for brasilicardins, we
recently revisited this strain and reinvestigated the correspond-
ing biosynthetic gene cluster, reported by Dairi and co-
workers.[22] Within the framework of this study, we sequenced
the whole genome of IFM 0406,[23] were able to redefine the
borders of the gene cluster and achieved the heterologous
expression of brasilicardin C.[24] Further analysis of the whole
genome sequence indicated a gene cluster encoding a new
nocobactin-like compound.
Structurally, nocobactins feature a C-terminal N  OH-cyclo-
lysine bound to a long chain 3-OH fatty acid, whose hydroxy
group is esterified by Nɛ-acyl-Nɛ-hydroxy-l-lysine. The α-amino
group of lysine is in turn linked to a 2-OH-phenyl-5-methyl-
oxazole moiety. To date, a series of differently substituted
congeners has been isolated from Nocardia species,[25–30]
showing variation in the substitution pattern of the 2-OH-
phenyl residue, of the oxazole ring system and of the ɛ-nitrogen
atoms of both lysine residues, or in the nature of the fatty acid
(Table 1).
In this study, we describe the in silico identification of a new
nocobactin biosynthetic gene cluster. Subsequently, the iso-
lation, structure elucidation and biological evaluation of the
resultant compounds, which we termed terpenibactins A  C, is
presented.
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Results and Discussion
Identification and organization of the terpenibactin (ter)
biosynthetic gene cluster
In silico whole genome sequence analysis of N. terpenica IFM
0406 using the bioinformatics web-tool antiSMASH 5.1.0[31]
revealed the presence of 38 biosynthetic gene clusters (BGCs).
Besides the readily identifiable known BGCs coding for
nocavionin,[14] brasilinolide,[17] brasilicardin,[23,24] and ectoine,[32]
two NRPS-PKS hybrid-based BGCs, both located on contig_9
(accession no. LWGR01000021.1), were postulated to direct the
biosynthesis of a nocobactin/mycobactin-like siderophore.
Closer inspection of this BGC showed that it extensively
parallels the nocobactin NA cluster.[33] Both share nine homo-
logues genes out of ten genes in total and both are divided
into two sub-gene clusters (sub-gene cluster 1 and 2). In the
case of the ter gene cluster, the inter-subcluster region spans
282 kb (Figure 1). Slight differences exist in the fact that the
NRPS nbtF homologue terF is located in sub-gene cluster 2 as
opposed to sub-gene cluster 1, and instead of a lysine
acetyltransferase similar to NbtH, the corresponding gene terH
codes for a lysine formyltransferase that is located at the
equivalent position in cluster one (Figure 1).
Having identified the split BGC, we predicted the resultant
biosynthetic route.[33] Salicylate is synthesised from chorismate
by the salicylate synthase TerS and activated by the salicylate-
AMP ligase TerT, being tethered to the aryl carrier protein
(ArCP) domain on the nonribosomal peptide synthetase (NRPS)
TerF (Figure 2).
Here, threonine is also activated and cyclised, giving either
2-hydroxyphenyl-5-methyloxazoline or 2-hydroxyphenyl-5-
methyloxazole. Recently, the candidate gene sagB, encoding a
dehydrogenase, was recognised to be responsible for the
oxidative function necessary to transform an oxazoline into an
oxazole (personal communication D.M, N.Z.). Since, neither the
related BGC nor the genetic environment surrounding con-
tained a homologue of sagB, we predicted that terpenibactins
bear a 2-hydroxyphenyl-5-methyloxazoline residue. Subse-
quently, the peptide backbone is extended through the
condensation of N6-formyl-N6-hydroxy-l-lysine by the NRPS
TerD. Since Thomas and co-workers demonstrated that the A
domain of a close homologue of TerD is specific for Nɛ-acyl-Nɛ-
hydroxy-l-lysine,[34] the tailoring of the lysine residue by the
lysine-N-oxygenase TerG and the lysine formyltransferase TerH
occurs prior to their insertion into the nocobactin skeleton. The
additional C domain within the NRPS terD is predicted to
condense a 3-hydroxy-2-methyl fatty acid unit into the growing
skeleton. The polyketide synthases TerB and TerC are expected
to work in conjunction to incorporate the fatty acid into the
biosynthesis. Due to the fact that fatty acids of this length
cannot be synthesised by a single type I PKS module, it is
hypothesised that TerC can select and carry long-chain fatty
acids.[33] Since the biosynthesis utilises fatty acids from primary
metabolism, it is typically challenging to predict the lengths of
the acyl chains on the basis of information gleaned from
bioinformatics alone; however, considering the range of the
nocobactin compound family (Table 1), we assumed the
precedence of fatty acid chains between C7-C17 units long.
Finally, the NRPS TerE then serves to epimerise and condense a
Table 1. The nocobactin compound family.
Compound R1 R2 R3 R4 R5 R6 R7 R8 R9 m/z Ref.
nocobactin NA-a OH H C9H19 CH3 OH – CH3 – H 743.4 [25]
nocobactin NA-b OH H C11H23 CH3 OH – CH3 – H 771.4 [25]
formobactin OH CH3 C9H19 H OH – CH3 – H 743.4 [26]
amamistatin A OH CH3 C7H15 H OH – CH3 – OCH3 745.4 [27]
amamistatin B H CH3 C7H15 H H – CH3 – OCH3 713.4 [27]
brasilibactin A OH H C15H31 H OH H H H H 801.5 [28]
nocardimicin A OH H C9H19 CH3 OH – H – H 729.4 [29]
nocardimicin B OH H C11H23 CH3 OH – H – H 757.4 [29]
nocardimicin C H H C11H23 CH3 OH – H – H 741.4 [29]
nocardimicin D OH H C13H27 CH3 OH – H – H 785.5 [29]
nocardimicin E H H C13H27 CH3 OH – H – H 769.5 [29]
nocardimicin F OH H C15H31 CH3 OH – H – H 813.5 [29]
nocardimicin G OH H C13H27 H OH H H H H 773.5 [30]
nocardimicin H OH H C15H31 H OH H H H H 801.5 [30]
nocardimicin I OH H C17H35 H OH H H H H 829.5 [30]
predicted cpd. OH H C7H15  C17H35 H OH H CH3 H H 703–844 this study
ChemBioChem
Full Papers
doi.org/10.1002/cbic.202000062
2ChemBioChem 2020, 21, 1–10 www.chembiochem.org © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
These are not the final page numbers! ��
Wiley VCH Donnerstag, 02.04.2020
2099 / 163179 [S. 2/10] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
N-hydroxy-lysine residue, which is subsequently lactamised,
most likely in a non-enzymatic way.[35]
In conclusion, the newly identified gene cluster in strain IFM
0406 was predicted to produce nocobactin-like compounds
with R1=R5=OH, R2=R4=R6=R8=R9=H, R7=CH3 and R
3
ranging from C7H15 to C17H35. With these substituents, the
resultant compounds should give rise to a suggested mass
between 703 and 844 Da. The predicted compounds most
closely resemble brasilibactin A or nocardimicins G  I (Table 1),
but bear a methyl-oxazoline instead of an oxazoline ring
system. The finding that terF codes for a threonine-specific A
domain that leads, in combination with the absence of sagB, to
the formation of a methyl-oxazoline ring system, was pivotal.
This fact enabled us to conclude that, regardless of the length
of the lipid side chain, the ter BGC had to give rise to
production of one or more new nocobactin-like compound(s).
LC/MS screening for the products of the terpenibactin (ter)
gene cluster
Methanol extracts of N. terpenica IFM 0406 cell pellets were
tested for the presence of nocobactin derivatives. A similar
strategy was adopted to that used in the isolation of nocobactin
NA and similar compounds.[25–30] It was intended that extracts
would be monitored for compounds in the mass range of 703–
Figure 1. Comparison of the biosynthetic gene clusters encoding (top) nocobactin NA and (bottom) novel terpenibactins.
Figure 2. Detailed view of PKS (orange boxes) and NRPS (green boxes) modules in the terpenibactin gene cluster of N. terpenica IFM 0406, including A domain
substrate specificities.
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844 Da by use of low-resolution (LR)-LC/MS. The use of chrome
azurol S (CAS) assays[36] to detect the siderophore of interest
proved inapplicable in this isolation effort, given that control
extracts of rich, orange-coloured production medium generated
false-positive CAS results. Foreseeing the possibility that any
secreted siderophores might be complexed with iron at the
point of analysis, and knowing from previous literature that
ferric nocobactin NA has an absorbance maximum at around
470 nm, extracts were also monitored at this wavelength in
HPLC analysis, in addition to the expected maxima produced by
the free ligand of 210, 260 and 310 nm.[25]
Analysis of cell pellet methanol extracts via LR-LC/MS led to
the detection of three peaks with absorbance at 460 nm and
masses within the range anticipated for the sought-after
compounds (M=815.8, 841.9 and 843.8 Da). Each compound
was detected as their singly charged [M+H]+ pseudomolecular
ion along with their ferrated form [M-3H+Fe3+ +H]+ and the
sodium adduct [M-3H+Fe3+ +Na]+ of the latter (see Figures S1
and S2 in the Supporting Information). In summary, the MS
data did not match any known compound from the nocobactin
family (Table 1) and therefore suggested that IFM 0406
produced at least three new siderophores, which were given
the trivial names terpenibactin A (1), B (2) and C (3).
Isolation and structure elucidation of terpenibactins A–C
To obtain sufficient material to support structural character-
ization, a 1 L fermentation was performed. Fractionation and
purification of the MeOH extract of the cell pellet was carried
out by both reversed-phase (RP) vacuum liquid chromatogra-
phy (VLC) and RP-HPLC. In this way, compounds 1–3 were
obtained in a ferrated form (Figure S3). However, due to
paramagnetic iron’s interference with the magnetic field, which
leads to peak broadening and poorly resolved NMR spectra,
complete iron removal was necessary in order to perform
structure elucidation. Since the method originally described by
Ratledge and Snow for full decomplexation of ferric
nocobactin[25] proved to be inefficient in our hands, we
converted the ferric forms of 1–3 into their corresponding
gallium salts and re-purified them by employing HPLC
(Figures S4 and S5).[37,38]
The analysis of the GaIII adduct of terpenibactin A (1) by HR-
ESI-MS determined its exact mass to be m/z 882.4156,
consistent with the molecular formula C43H67GaN5O10 (Δ
1.4 ppm), indicating a structure with 12 degrees of unsatura-
tion. The IR spectrum (Figure S6) possessed absorptions for
ester (1738 cm  1) and amide (1672 cm  1) carbonyl groups and
an aromatic ring system (1617, 1464, 857, 757, 699 cm  1). UV
maxima observed at 219 and 255 and 339 nm (Figure S7) were
indicative of a substituted benzenoid chromophore with an
extended conjugated system. In the 13C and DEPT135 NMR
spectra (Figures S10 and S11), signals assignable to 43 carbons
were detected, including those for seven quaternary carbons,
one N-formyl (δ 155.3, 1JC,H=209 Hz), four sp
2 methines, six sp3
methines, 22 methylenes and three methyl groups (Table 2).
These data also revealed the presence of nine double bonds
(3×CC, 1×CN, 5×CO); thus, 1 was found to be tricyclic. Analysis
of the 1H,1H COSY and 1H,13C HSQC-TOCSY spectrum resolved
the partial structures A  E (Figure 3), which were connected by
using 1H,13C HMBC and 1H,1H NOESY correlations (Figures S13–
S16).
The 1H,1H connectivities from H-3 to H-6 and their 1H and
13C chemical shifts in combination with the 1H,1H coupling
pattern indicated the presence of a 1,2-disubstituted benzene
ring. The chemical shift of C-2 (δ 167.5) and 1H,13C HMBC cross
correlations between H-3/C-1, H-4/C-2 and H-5/C-1 showed that
fragment A consisted of a benzene ring that was substituted
with a phenolic hydroxyl group at C-2. The 13C NMR chemical
shifts for C-7, C-9, and C-10, together with the doublet proton
resonance at δ 1.49 (H-13), as well as the long-range CH
couplings observed between H-10/C-7, H-10/C-12 and H-9/C-12,
were all indicative of the presence of a methyl-dihydrooxazole
carboxylic acid moiety, which represents fragment B. A long-
range CH coupling between H-6 and C-7 allowed the
connectivity between C-1 to C-7, and thus that between
fragment A and B, to give 9,10-dihydro-asteroidic acid. The
typical 1H and 13C chemical shifts, together with the connected
spin system, identified fragment C as a lysine residue. 1H,13C
HMBC long-range correlations between its α-proton and Lys1-
Figure 3. 1H,1H COSY and 1H,13C HSQC-TOCSY (bold lines), selected 1H,13C long-range (red arrows) and selected 1H,1H NOESY (dashed blue lines) correlations for
terpenibactin A (1). HMFA: hydroxymethyl fatty acid.
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Table 2. 1H and 13C NMR spectroscopic data for terpenibactins A–C (1–3).[a]
Atom Terpenibactin A (1) [b] Terpenibactin B (2) [b] Terpenibactin C (3) [b]
δH δC
[c] δH δC
[c] δH δC
[c]
9,10-Dihydro-asteroidic acid
1 110.5, qC 110.5, qC 110.5, qC
2 167.5, qC 167.5, qC 167.5, qC
3 6.81, d (8.5) 122.8, CH 6.81, d (8.5) 122.8, CH 6.81, d (8.5) 122.8, CH
4 7.36, ddd (8.7, 7.9, 1.8) 137.0, CH 7.36, ddd (8.7, 7.9, 1.8) 137.0, CH 7.36, ddd (8.7, 7.9, 1.8) 137.0, CH
5 6.68, t (7.6) 117.3, CH 6.68, t (7.6) 117.3, CH 6.68, t (7.6) 117.3, CH
6 7.67, dd (8.1, 1.8) 130.8, CH 7.67, dd (8.1, 1.8) 130.8, CH 7.67, dd (8.1, 1.8) 130.8, CH
7 171.89, qC[d] 171.89, qC[d] 171.89, qC[d]
9 5.27, dd (5.1, 6.3) 81.0, CH 5.27, dd (5.1, 6.3) 81.0, CH 5.27, dd (5.1, 6.3) 81.0, CH
10 4.31, d (5.1) 73.2, CH 4.31, d (5.1) 73.2, CH 4.30, d (5.2) 73.2, CH
12 170.8, qC 170.8, qC 170.8, qC
13 1.49, d (6.3) 21.3, CH3 1.49, d (6.3) 21.3, CH3 1.49, d (6.3) 21.3, CH3
Lys1
C=O 171.95, qC[d] 171.96, qC[d] 171.95, qC[d]
α 4.39, m 54.9, CH
[54.8]
4.39, m 54.9, CH 4.39, m 54.9, CH
[54.8]
β 2.10, m 27.5, CH2 2.10, m 27.5, CH2 2.10, m 27.5, CH2
γ 1.60, m
1.97, m
19.7, CH2 1.60, m
1.97, m
19.7, CH2 1.60, m
1.97, m
19.7, CH2
δ 1.89, m 29.9, CH2 1.89, m 29.9, CH2 1.89, m 29.9, CH2
ɛ 3.70, m
3.95, m
49.5, CH2 3.70, m
3.95, m
49.5, CH2 3.70, m
3.95, m
49.5, CH2
NH 9.21, d (4.7) 9.20, d (4.7) 9.21, d (4.7)
Nɛ  CH=O 8.13,s 155.3, CHO 155.3, CHO 155.3, CHO
Hydroxymethyl fatty acid
1’ 173.8, qC
[173.9]
173.8, qC 173.8, qC
[173.9]
2’ 2.62, m 45.26, CH
[45.31]
2.62, m 45.3, CH 2.62, m 45.26, CH
[45.31]
3’ 5.11, dt (2.0, 10.0) 78.0, CH 5.11, dt (2.0, 10.0) 78.0, CH 5.11, dt (2.0, 10.0) 78.0, CH
4’ 1.49, m 30.2, CH2 1.49, m 30.2, CH2 1.49, m 30.2, CH2
5’ 1.21, m 26.9, CH2 2.04, m 28.2, CH2 1.21, m 26.9, CH2
6’ 1.30, m 30.6, CH2 5.35, t (4.5) 130.8, CH 1.30, m 30.6, CH2
7’ 1.30, m 30.6, CH2 5.35, t (4.5) 130.8, CH 1.30, m 30.6, CH2
8’ 1.30, m 30.6, CH2 2.04 m 28.2, CH2 1.30, m 30.6, CH2
9’ 1.30, m 30.6, CH2 1.30, m 30.6, CH2 1.30, m 30.6, CH2
10’ 1.30, m 30.6, CH2 1.30, m 30.6, CH2 1.30, m 30.6, CH2
11’ 1.30, m 30.6, CH2 1.30, m 30.6, CH2 1.30, m 30.6, CH2
12’ 1.30, m 30.6, CH2 1.30, m 30.6, CH2 1.30, m 30.6, CH2
13’ 1.30, m 30.6, CH2 1.30, m 30.6, CH2 1.30, m 30.6, CH2
14’ 1.30, m 30.6, CH2 1.30, m 30.6, CH2 1.30, m 30.6, CH2
15’ 1.30, m 30.6, CH2 1.30, m 30.6, CH2 1.30, m 30.6, CH2
16’ 1.30, m 33.1, CH2 1.30, m 30.6, CH2 1.30, m 30.6, CH2
17’ 1.32, m 23.7, CH2 1.30, m 30.6, CH2 1.30, m 33.1, CH2
18’ 0.92, br t (6.9) 14.5, CH3 1.30, m 33.1, CH2 1.32, m 23.7, CH2
19’ 1.32, m 23.7, CH2 1.30, m 30.6, CH2
20’ 0.92, br t (6.9) 14.5, CH3 0.92, br t (6.9) 14.5, CH3
2’-Me 1.14, d (7.2) 14.2, CH3 1.14, d (7.3) 14.2, CH3 1.14, d (7.2) 14.2, CH3
Lys2
C=O 166.4, qC 166.4, qC 166.4, qC
α 4.79, m 51.2, CH
[51.3]
4.79, m 51.2, CH 4.79, m 51.2, CH
[51.3]
β 1.48, m
1.95, m
31.68, CH2
[31.70]
1.48, m
1.95, m
31.7, CH2 1.48, m
1.95, m
31.68, CH2
[31.70]
γ 2.05, m 28.9, CH2 2.05, m 28.9, CH2 2.05, m 28.9, CH2
δ 1.80, m 25.6, CH2 1.80, m 25.6, CH2 1.80, m 25.6, CH2
ɛ 3.85, m
3.99, m
54.4, CH2 3.85, m
3.99, m
54.4, CH2 3.85, m
3.99, m
54.4, CH2
NH n. o.[e] n. o.[e] n. o.[e]
Nɛ  C=O 155.3, qC 155.3, qC 155.3, qC
[a] Measured at 400 (1H) and 100 MHz (13C) in d4-MeOH. [b] Coupling constants (J) are in parentheses and reported in Hz; chemical shifts are given in ppm. [c]
Multiplicities were deduced from DEPT135 and multiplicity edited 1H,13C HSQC NMR experiments. 13C NMR shift values in squared brackets represent a minor
conformer (ratio 3:1). [d] Assignments within a column may be interchanged. [e] n.o.: not observed.
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CO, and 1H,1H NOESY through-space interactions between the
ɛ-methylene protons and the formyl hydrogen, defined the
complete moiety as N-formyl-Lys1. In a similar fashion, fragment
E was established as a second lysine residue (Lys2). However,
the observation of a correlation between the α-proton and the
corresponding the ɛ-methylene protons in the 1H,1H NOESY
spectrum indicated that Lys2 was cyclic, hence forming an ɛ-
aminocaprolactam ring.
The last major fragment, D, was deduced as 2-methyl-3-
hydroxyoctadecanoic acid on the basis of the analysis of COSY
and HSQC-TOCSY spectra, together with the 1H,13C long-range
couplings from both H-2’ and its 2’-methyl hydrogens to C-1’.
The length of the alkyl chain was corroborated by ESI-MS/MS
fragment ions. The connectivity of fragment D and E via Lys2-
NH resulted from cross peaks in the HMBC spectrum between
the α-proton of Lys2 and C-1’. Coupling between H-3’ and Lys1-
CO placed partial structure D adjacent to C through an ester
bond. Furthermore, the α-proton of Lys1 exhibited HMBC
couplings to C-12, which allowed the connection of partial
structure C to B through an amide bond. Taking the molecular
formula of 1 into consideration, the remaining two hydroxyl
groups were assigned to substituents at the ɛ-nitrogen atoms
of each lysine residue. This deduction was also supported by
MS/MS fragment ions at m/z 145 and 423 (Figure S17). With the
planar structure of 1 determined, the configuration at C-2’, C-3’,
C-9, C-10 and the lysine residues required elucidation.
The absolute configuration of the amino acid-related
moieties was inferred in silico from the BGC. In an NRPS context,
the epimerization (E) domains and combined condensation/
epimerization (C/E) domains determine the absolute config-
uration during the biosynthesis process. An E domain was
identified in TerE, thus indicating conversion of the activated
amino acid Lys2 into the D-configuration. The absence of C/E
and E domains in the nonribosomal peptide synthetases TerF
and TerD suggests the incorporation and processing of L-
configured Thr and Lys1 moieties. In conclusion, from bio-
informatics, the stereochemistry was predicted as 10S, 9R, l-(S)-
Lys1 and d-(R)-Lys2. Concerning the lysine residues, these
findings are in agreement with the absolute configuration
determined for nocobactin NA. The relative stereochemistry at
C-2’-C-3’ of the 2-methyl-3-hydroxyoctadecanoic acid was
assigned as erythro on the basis of the high similarity of 1H and
13C NMR shifts and JH,H values between 1 and brasilibactin A.
Thus, the structure of terpenibactin A was elucidated to be 1 as
shown in Figure 4. With these features, terpenibactin A (1) is
most closely related to nocardimicin H, but bears a methyl
group instead of a hydrogen atom at R7 (Figure 4 and Table 1).
Terpenibactin B (2) gave a quasi-molecular ion [M-3H+
Ga3+ +H]+ at m/z 908.4335 in the HR-ESI-MS, appropriate for
the molecular formula C45H69GaN5O10 (Δ 3.8 ppm) and corre-
sponding to 13 degrees of unsaturation. Thus, terpenibactin B
(2) differs from terpenibactin A (1) by a C2H2 group and an
additional double bond equivalent. The 1H and 13C NMR spectra
of 2 were highly similar to those of 1. However, the 13C NMR in
particular showed elevated signal intensity in the double bond
region at δC 130.9 and additional, heightened resonances at δC
28.2. Since both resonances integrated for two carbons, it was
hypothesised that 2 constitutes a double bond between two
magnetically equivalent carbon atoms. The HSQC-TOCSY NMR
experiment proved that both resonances were part of the spin
system of the hydroxymethyl fatty acid of 2. Detailed analysis of
the 1H,1H COSY and CH long-range correlations enabled the
assignment of Δ6’,7’ double bond in 2. Its olefinic coupling
constant (3JH,H=4.5 Hz) showed that Δ
6’,7’ has Z geometry. For
biogenetic reasons, the same absolute configuration, as given
in 1, is suggested for the remaining chiral centres of 2.
Terpenibactin B (2) thus most closely resembles nocardimicin I.
However, by comparison, 2 bears a methyl group at R7 of the
oxazoline ring system and a double bond in the lipid side chain
R3 (Figure 4 and Table 1).
The molecular formula of terpenibactin C (3) was estab-
lished as C45H71GaN5O10 on the basis of HR-ESI-MS. The
1H and
13C NMR spectra were virtually identical with those of
terpenibactin A(1). The MS/MS fragmentation pattern of 3
readily unveiled that the mass shift of 28 mass units (2
methylenes) is attributable to a difference in length of the
incorporated fatty acid. Thus, 3 possesses a 2-methyl-3-
hydroxyeicosanoic acid moiety instead of a 2-methyl-3-hydroxy-
octadecanoic acid in 1. Consequently, terpenibactin C repre-
sents a highly similar congener of nocardimicin I, but 3
possesses a methyl-oxazoline instead of an oxazoline ring
system (Figure 4 and Table 1).
Biological properties of terpenibactins A–C
As several nocobactins have shown outstanding
antimicrobial,[28] cytotoxic[25,28] and highly selective muscarinic
M3 receptor inhibitory[29,30] properties, we evaluated the gallium
Figure 4. Chemical structures of terpenibactins A  C.
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(III)-chelated terpenibactins A  C (1–3) in corresponding assays.
In standardised antimicrobial assays by broth microdilutions,[39]
compounds 1–3 were all inactive up to the highest concen-
tration tested (64 μg/mL), while in a cytotoxicity assay using
HeLa cells, the compounds exhibited moderate bioactivity. By
contrast, all three compounds showed potent muscarinic M3
receptor inhibitory activity, with IC50 values ranging from 1.15
to 1.77 μM (Table 3). The latter results are in good agreement
with the IC50 values reported for the structurally related
nocardimicins A  H, which ranged from 0.37 to 5.89 μM.[29,30]
Sakagami and co-workers demonstrated that iron(III)-chelated
nocobactins exhibit cytotoxic activity that is two orders lower
than of the corresponding iron-free forms.[25] It is conceivable
that the gallium-chelated terpenibactins A  C are affected in a
similar fashion, which could explain why compounds 1–3 were
found to be inactive in the antimicrobial assay and only
moderately active in the cytotoxicity assay.
Conclusion
Using a bioinformatics approach, we initially deduced already
from the in silico analysis that the resultant secondary
metabolite is new and confirmed the prediction by spectro-
scopic means. Considering the large number of nocobactins,
terpenibactins represent another example of Nature’s aptitude
in combinatorial chemistry, that is, in this case, through the
natural diversification of molecules simply by modification of A-
domain substrate specificity, C-domain promiscuity and the
presence of dehydrogenases or the efficacy of hydroxylation
enzymes. Furthermore, we confirmed the antimuscarinic effect
of this compound class, which was already reported for
nocardimicins. The addition of terpenibactins to the compound
family allowed us to deduce that the antimuscarinic effect of
nocobactins appears not to be influenced by the change of the
oxidation status of the oxazoline ring, neither by the meth-
ylation (serine vs. threonine incorporation) nor by the type of
Nɛ-acylation (formylation vs. acetylation). Together with the M3-
receptor subtype specificity, found with the nocardimicins, and
the moderate cytotoxicity, nocobactins possibly represent an
interesting pharmacophore for the development of M3-receptor
selective muscarinic inhibitors.
Experimental Section
General procedures: Optical rotation values were measured on a
Jasco P-2000 polarimeter, using a 3.5 mm×10 mm cylindrical
quartz cell. UV spectra were recorded on a PerkinElmer Lambda
25 UV/Vis spectrometer. Infrared spectra were obtained by employ-
ing a Jasco FTIR 4200 spectrometer, interfaced with a MIRacle ATR
device (ZnSe crystal). HPLC was performed with a Waters system
comprising a Waters 1525 binary pump with a 7725i Rheodyne
injection port, a Kromega solvent degasser and a Waters 996
photodiode array detector. For low-resolution LC/MS analysis, an
1100 Series HPLC system (Agilent Technologies) was fitted with a
G1322 A degasser, a G1312 A binary pump, a G1329 A autosampler,
and a G1315 A diode array detector. The Agilent HPLC components
were connected with an ABSCIEX 3200 Q TRAP LC/MS/MS mass
spectrometer (Sciex, Darmstadt, Germany). 1D and 2D NMR spectra
were measured on a Bruker Avance II 400 HD spectrometer using a
5 mm SMART probe head. All NMR spectra were recorded in d4-
MeOH, processed with TopSpin 3.5 and MestReNova 12.0.4 and
calibrated to the residual solvent signals (δH/C 3.31/49.0). High-
resolution mass spectra were acquired on an HR-ESI-TOF-MS maXis
4G mass spectrometer (Bruker). All solvents were purchased as
HPLC or LC/MS grade. Chemicals were purchased from Sigma-
Aldrich or VWR. Steam sterilization of medium components and
waste were performed at 121 °C for 15 min at 2.1 bar using a Systec
VX-150 autoclave, equipped with air exhaust filtration.
Bacterial material and cultivation conditions: The producer strain
N. terpenica IFM 0406 was purchased from the culture collection of
the Medical Mycology Research Center (MMRC), Chiba University,
Chiba, Japan. For cultivation, a protocol conceived by Ikeda et al.[29a]
was adapted. 100 mL of preculture medium (consisting of 10 g/L
soluble starch, 5 g/L glucose, 3 g/L NZ-case, 2 g/L yeast extract, 5 g/
L tryptone, 1 g/L K2HPO4, 0.5 g/L MgSO4 and 3 g/L CaCO3, adjusted
to pH 7.0 before sterilization) in a 500 mL baffled Erlenmayer flask
was inoculated with a loopful of a 3-day-old agar culture of the
strain, and shaken at 150 rpm at 37 °C for five days, using an
INFORS HT Multitron Pro orbital incubator shaker. 3 mL of this
culture was in turn used to inoculate 200 mL volumes of production
medium (consisting of 5 g/L glucose, 20 g/L glycerol, 20 g/L soluble
starch, 15 g/L Pharmamedia and 3 g/L yeast extract, adjusted to
pH 7.0 before sterilization) in 500 mL Erlenmeyer flasks. Fermenta-
tion was carried out at 30 °C at 150 rpm for five days.
LC/MS screening: Following small scale cultivation (200 mL),
cultures were centrifuged in a Thermo Scientific Heraeus Multifuge
4KR centrifuge at 5346 g for 10 min. Subsequently, the supernatant
was extracted with ethyl acetate (1 :1), while the cell pellet was
extracted with 200 mL methanol. Upon evaporation of each extract
under reduced pressure, the resultant crude extracts of each
experiment were dissolved in methanol with a few drops of water,
centrifuged to remove detritus prior to analysis, and profiled by LC/
MS using a MeOH/H2O gradient, increasing the MeOH portion from
50 to 100% over 20 min, followed by isocratic elution at 100%
MeOH for an additional 20 min (Phenomenex Luna C18 (2)–100 Å
column, 250×2.0 mm, 5 μm; 0.2 mL/min flow rate; with total ion
current [Q3 MS positive scan mode] and photodiode array
monitoring). The following MS parameters were used for this
analysis: declustering potential: 70 V; entrance potential: 10 V;
curtain gas: 10 psi; collision gas: 2 psi; ion spray source voltage:
4500 V; additional temperature: 450 °C, ion source gas 1 (nebuliser
gas): 50 psi; ion source gas 2 (drying gas): 50 psi.
Isolation and extraction: All the broth from a 1 L fermentation of
IFM 0406 was centrifuged, the cell pellet extracted with 6×200 mL
MeOH, and evaporated to dryness. The cell pellet extract was
resuspended and further fractionated via vacuum liquid chroma-
tography (VLC). The reversed-phase (RP) C18 column (dimensions:
10×5 cm; material: Macherey-Nagel Polygoprep 50–60 C18 RP silica
gel) was eluted stepwise under vacuum with solvents of decreasing
polarity (300 mL per fraction), ranging from a 50 :50 MeOH/H2O
mixture to pure methanol, followed by 100% dichloromethane to
Table 3. Biological activities of 1–3.
Compound Muscarinic M3 receptor
inhibitory activity
Cytotoxicity
IC50 IC50 (HeLa)
terpenibactin A (1) 1.15�0.13 μM 16.7 μg/mL
terpenibactin B (2) 1.77�0.26 μM 45.9 μg/mL
terpenibactin C (3) 1.59�0.13 μM 33.3 μg/mL
atropine 8.10�0.80 nM N/A
ChemBioChem
Full Papers
doi.org/10.1002/cbic.202000062
7ChemBioChem 2020, 21, 1–10 www.chembiochem.org © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
These are not the final page numbers! ��
Wiley VCH Donnerstag, 02.04.2020
2099 / 163179 [S. 7/10] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
give seven fractions (A  G). Fraction G, eluting with 100% dichloro-
methane, was further purified by RP-HPLC using a linear gradient
from 50 :50 to 100:0 (MeOH/H2O) over a period of 10 min, followed
by isocratic elution at 100% MeOH for an additional 25 min
(Phenomenex Aeris Peptide XB  C18 column, 4.6×250 mm, 3.6 μm;
0.6 mL/min flow rate, UV monitoring at 340 and 460 nm), which
yielded pure terpenibactins A (13.6 mg), B (10.9 mg) and C (7.4 mg).
GaIII-complex formation: A suspension of 5 mg gallium sulphate in
30 mL MeOH:H2O (1 :1) was added to a near-dry fresh methanol
pellet extract, and the sample rotated for one hour. This was then
evaporated to dryness, resuspended in methanol and analysed
using LR-LC/MS. Results showed that three new peaks had formed
alongside the ferrated components, with higher intensities and
masses corresponding to the gallium-complexed forms of their
ferrated neighbours. Notably, repeated LR-LC/MS analysis, two days
after the run that first evidenced the formation of gallium
complexes, demonstrated that only trace amounts remained of the
ferrated forms of the compounds of interest, suggesting a time-
dependent complete interconversion of iron to gallium complexes
even within a sample dried and stored at   20 °C.
Chrome azurol S (CAS)-assay: The CAS assay agar plates for the
detection of siderophores were prepared on a 100 mL scale as
previously described.[36]
Antibacterial assays: The minimal inhibitory concentration (MIC)
was determined in cation-adjusted Mueller-Hinton medium that
contains casein, beef extract and starch by using a twofold serial
dilution method according to the standards and guidelines of the
Clinical and Laboratory Standards Institute (CLSI).[39] In brief, a
twofold serial dilution of the test compound was prepared in
microtiter plates and seeded using a final test concentration of
bacteria of 5×105 colony-forming units per mL. After the overnight
incubation at 37 °C, the MIC was determined as the lowest
compound concentration preventing visible bacterial growth. The
strain panel included representative species of nosocomial patho-
gens, which are known as “ESKAPE” bacteria. Specifically, the
following strains were used: Enterococcus faecium BM 4147–1,
Staphylococcus aureus ATCC 29213, Klebsiella pneumoniae ATCC
12657, Acinetobacter baumannii 09987, Pseudomonas aeruginosa
ATCC 27853 and Enterobacter aerogenes ATCC 13048. Bacillus
subtilis 168 and Escherichia coli ATCC 25922 were used as further
reference strains. The ATCC strains were provided by the American
Type Culture Collection. A. baumannii 09987 was obtained from the
University of Bonn, Germany.
Cytotoxicity assay: The cytotoxicity test against the HeLa human
cervical carcinoma cell line was performed in RPMI cell culture
medium supplemented with 10% foetal bovine serum using the 7-
hydroxy-3H-phenoxazin-3-one-10-oxide (resazurin) assay. A twofold
serial dilution of the test compounds was prepared in duplicates in
a microtiter plate and seeded with trypsinised HeLa cells to a final
cell concentration of 1×104 cells per well. After 24 h incubation at
37 °C, 5% CO2, 95% relative humidity, resazurin was added at a final
concentration of 200 μM, and cells were again incubated overnight.
Cell viability was assessed by determining the reduction of
resazurin to the fluorescent resorufin. Fluorescence was measured
in a TECAN M200 reader at an excitation wavelength of 560 nm and
an emission wavelength of 600 nm in relation to an untreated
control.
Muscarinic M3 receptor calcium flux assay: Chem-1 frozen cells,
stably transfected with a clone of the human M3 muscarinic
acetylcholine receptor (CHRM3 cDNA, HTS116RTA), were purchased
from Eurofins Pharma Bioanalytical Services US Inc. They were
thawed, suspended and seeded in 96-well plates containing the
media component according to the manufacturer’s instructions.
The assay plates were then incubated overnight at 37 °C in a 5%
CO2 humidified atmosphere, during which the cell adhered to the
bottom of the wells, followed by the removal of media components
prior to use in the calcium assay.
Cytosolic-free calcium concentration ([Ca2+]i) was measured using
the calcium mobilization assay with fluorescent dyes. The dye-
loading solution containing Fluo-8 NW Ca2+ dye, 10X Pluronic®
F127 Plus and Hanks’ buffer with 20 mM HEPES was prepared
according to the Screen QuestTM Fluo-8 NW calcium assay kit (AAT
Bioquest). Probenecid acid was not applied to this method. At the
start of the assay, the 96-well plates containing Chem-1 cells were
loaded with an equal volume of dye-loading solutions at 37 °C for
1 h. Afterwards, the cells were pre-incubated with the GPCR-
antagonist test compounds terpenibactin A, B, and C for 30 min
prior to the injection of the acetylcholine agonist (Sigma) at the
final concentration of 250 nM. The final volume was 100 μL per
well. The changes in fluorescence intensities in response to the
indicated ligand were measured using a Tecan Infinite M200®
injection system with a filter set for excitation and emission at 490
and 525 nm, respectively. IC50 values and associated SEMs were
calculated by curve-fitting the relative fluorescence unit data to an
sigmoidal model using GraphPad Prism 7.00.
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 Figure S01. LR-LC/MS Q3 positive mode scan of N. terpenica IFM 0406 methanol extract 
showing (top to bottom) ions at m/z 816, 842 and 844 (green) accompanied by ions at m/z 
869, 895 and 897 (red) and their sodium adducts (orange) respectively, predicted to belong to 
novel nocobactin-like siderophores. Subsequent HR-ESI-MS analysis of these three peaks 
showed their sodium adducts as base peaks, with exact masses of exact masses of m/z 
891.4043, 917.4201 and 919.4358, matching closely with predicted chemical formulae of 
C43H66FeN5NaO10 (Δ-1.6 ppm), C45H68FeN5NaO10 (Δ-1.4 ppm) and C45H70FeN5NaO10 (Δ-1.3 
ppm). 
 
Figure S02. Expected structural formula of Fe(III)-bound nocobactin-like novel siderophores 
[M-3H+Fe3++H]+, where R = fatty acid chain of variable length and saturation. 
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 Figure S03. HPLC run, monitoring at 460 nm. Ferrated terpenibactins A-C appear at tR = 16 
to 18 min.  
 
 
Figure S04: LR-LC/MS of gallium-bound terpenibactins in positive mode. Top panel: extracted 
ion chromatogram of both iron- and gallium-bound novel siderophores, with gallium-bound 
forms (blue, red and green traces) showing higher intensities; bottom panel: base peak at m/z 
882 represents mass of Ga-bound terpenibactin A ([M-3H+Ga3++H]+). 
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C 
 Figure S05. HPLC run, monitoring at 340 nm. Gallium-bound terpenibactins A-C appear at tR 
= 19 to 23 min.  
 
 
Optical rotation value of 1:   [𝜶]𝟐𝟑𝑫   +93.9o (c 0.33, MeOH)  
 
 
 
Figure S06. IR spectrum of 1. 
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C 
  
Figure S07. UV spectrum of 1 in MeOH: λmax (log ε) 197 (3.06), 219 (2.64), 255 (2.11), 339 
(1.83) 
 
 
 
 
 
Figure S08. HR-ESI-MS analysis of Fe(III)-terpenibactin A with a base peak at m/z 891      
[M-3H+Fe3++Na]+. 
 
 Figure S09. 1H NMR spectrum (400 MHz) of 1 in d4-MeOH 
 
 
Figure S10. 13C NMR spectrum (100 MHz) of 1 in d4-MeOH  
 
 
 
Figure S11. DEPT135 NMR spectrum (100 MHz) of 1 in d4-MeOH  
 
Figure S12. 1H-13C HSQC NMR spectrum (400 MHz) of 1 in d4-MeOH  
 Figure S13. 1H-1H COSY NMR spectrum (400 MHz) of 1 in d4-MeOH  
 
 
Figure S14. 1H-13C HSQC-TOCSY NMR spectrum (400 MHz) of 1 in d4-MeOH  
 Figure S15. 1H-13C HMBC NMR spectrum (400 MHz) of 1 in d4-MeOH  
 
 
Figure S16. 1H-1H NOESY NMR spectrum (400 MHz) of 1 in d4-MeOH 
  
Figure S17. Top: Enlargement of HR-ESI-MS of terpenibactin A showing a fragment at m/z 
423 and rationalization of MS/MS fragmentation of terpenibactins A-C (bottom). 
 
 
 
 
 
 
 
 
 
 
 
 
Optical rotation value of 2:   [𝜶]𝟐𝟑𝑫   +57.6o (c 0.33, MeOH)  
 
Figure S18. 1H-NMR spectrum (400 MHz) of 2 in d4-MeOH  
 
 
Figure S19. 13C-NMR spectrum (100 MHz) of 2 in d4-MeOH  
  
Optical rotation value of 3:   [𝜶]𝟐𝟑𝑫   +75.8o (c 0.33, MeOH)  
 
 
Figure S20. 1H-NMR spectrum (400 MHz) of 3 in d4-MeOH  
 
 
Figure S21. 13C-NMR spectrum (100 MHz) of 3 in d4-MeOH  
 Figure S22. 1H-13C HSQC NMR spectrum (400 MHz) of 3 in d4-MeOH  
 
 
Figure S23. 1H-1H COSY NMR spectrum (400 MHz) of 3 in d4-MeOH  
 
 Figure S24. 1H-13C HSQC-TOCSY NMR spectrum (400 MHz) of 3 in d4-MeOH  
 
 
Figure S25. 1H-13C HMBC NMR spectrum (400 MHz) of 3 in d4-MeOH  
  
  
Figure S26. Calcium mobilisation assay in M3-expressing Chem-1 cells (data represent the 
mean of three independent experiments) using antagonist test compounds (terpenibactins A, 
B, and C) and positive antagonist control, atropine.  
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